

11/22/00
JC961 U.S. PTO

11-24-00

A

NEW UNITED STATES UTILITY PATENT APPLICATION TRANSMITTAL

Atty. Docket No.: 18093/1170

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that the paper (and any paper or fee referred to as being enclosed) is being deposited with the United States Postal Service using Express Mail to Addressee Service, under 37 C.F.R. Section 1.10, **Express Mail Label No. EL592002542US** on this date, **November 22, 2000**, postage prepaid, in an envelope addressed to Box: Patent Application, Commissioner for Patents, Washington, D.C. 20231.

Kimberly Coyne
Name of Person Mailing Paper

Kimberly Coyne
Signature of Person Mailing Paper

Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

Enclosed herewith is a new patent application of:

First Named Inventor (or application identifier): Richard Vile & Michael Gough

Title of Invention: Gene Expression by Positive Feedback Activation of a Cell Type-Specific Promoter

Type: ☒ New
☐ Continuation
☐ Continuation-in-Part
☐ Divisional

And includes the following papers:

1. ☒ Specification 47 pages (including specification, claims, abstract)/59 claims (3 independent)
2. ☒ Declaration/Power of Attorney is:
☐ attached ☐ executed ☐ unexecuted
☒ NOT included, but deferred under 37 C.F.R. § 1.53(f).
3. ☒ 27 Distinct sheets of ☐ Formal ☒ Informal Drawings
4. ☐ Preliminary Amendment.
5. ☐ Information Disclosure Statement
☐ Form 1449
☐ A copy of each cited prior art reference
6. ☐ Assignment with Recordation Cover Sheet.
7. ☒ Priority is hereby claimed under 35 U.S.C. § 119, based upon the following application(s):

Country	Application Number	Date of Filing (day, month, year)
United States	60/167,085	November 23, 1999

8. ☐ Priority is hereby claimed under 35 U.S.C. § 120 based upon the following application(s):

Country	Application Number	Date of Filing (day, month, year)

9. ☐ Priority document(s).

JC815 U.S. PTO
09/22/01
11/22/00

NEW UNITED STATES UTILITY PATENT APPLICATION TRANSMITTAL

Atty. Docket No.: 18093/1170

10. ☒ Statement of Small Entity Status, Pursuant to 37 C.F.R. §1.27.
11. ☐ Microfiche Computer Program (Appendix).
12. ☐ Nucleotide and/or Amino Acid Sequence Submission.
☐ Computer Readable Copy.
☐ Paper Copy (identical to computer copy).
☐ Statement verifying identity of above copies.
13. Calculation of Fees:

FEES FOR	TOTAL CLAIMS	EXCESS CLAIMS	FEE	AMOUNT DUE
Basic Filing Fee (37 C.F.R. § 1.16(a))				\$710.00
Total Claims in Excess of 20 (37 C.F.R. § 1.16(c))	59	39	\$18.00	\$702.00
Independent Claims in Excess of 3 (37 C.F.R. § 1.16(b))	3	0	\$80.00	\$0.00
Multiple Dependent Claims (37 C.F.R. § 1.16(d))	y		\$270.00	\$270.00
Subtotal - Filing Fee Due				\$1,682
Reduction by 50%, if Small Entity (37 C.F.R. §§ 1.9, 1.27, 1.28)	MULTIPLY BY 0.50			\$841.00
TOTAL FILING FEE DUE				\$841.00
Assignment Recordation Fee (if applicable) (37 C.F.R. § 1.21(h))	0		\$40.00	n/a
GRAND TOTAL DUE				\$841.00

14. PAYMENT is:
☒ included in the amount of \$841.00 by our enclosed check. The Commissioner is hereby authorized to charge any deficiencies in the fees to Deposit Account 16-0085, Ref. 18093/1170.
☐ not included, but deferred under 37 C.F.R. § 1.53(f).

15. All correspondence for the attached application should be directed to:

Kathleen M. Williams
Palmer & Dodge, LLP
One Beacon Street
Boston, MA 02108
Telephone: (617) 573-0100
Facsimile: (617) 227-4420

16. Other: Patent Data Entry Form


Respectfully submitted,

Date: November 22, 2000

By: Dianne Rees
Dianne Rees, Ph.D.
Registration No.: 45,281

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Richard Vile & Michael Gough
Serial No.: Not yet assigned
Filed: November 22, 2000
Entitled: Gene Expression by Positive Feedback
Activation of a Cell Type-Specific Promoter

**CERTIFICATE OF MAILING UNDER 37 CFR 1.10**

I hereby certify that the paper (and any paper or fee referred to as being enclosed) is being deposited with the United States Postal Service using Express Mail to Addressee Service, under 37 C.F.R. Section 1.10, **Express Mail Label No. EL592002542US** on this date, **November 22, 2000**, postage prepaid, in an envelope addressed to Box: Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

Kimberly Coyne
Name of Person Mailing Paper

Kimberly Coyne
Signature of Person Mailing Paper

Box: Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

1. New Utility Patent Application Transmittal;
2. Patent Application Specification, (47 pages);
3. (27) sheets of informal drawings;
4. Patent Data Entry Form;
5. Check in the amount of \$841.00 for the requisite filing fee; and
6. Return Post Card.

Pursuant to 37 C.F.R. § 1.27, Applicant claims small entity status.

The Assistant Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 18093/1170. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: November 22, 2000

Dianne Rees
Dianne Rees, Ph.D.
Registration No.:45,281
PALMER AND DODGE, LLP
One Beacon Street
Boston, MA 02109-3190
Telephone No: (617) 573-0100

00221391 11/22/00

Inventor Information

Inventor One Given Name: Richard
Family Name: Vile
Name Suffix:
Postal Address Line One: 2107 Washington Lane, SW
Postal Address Line Two:
City: Rochester
State/Province: MN
Country: USA
Postal or Zip Code: 55902
City of Residence: Rochester
State/Prov. of Residence: MN
Country of Residence: U.S.
Citizenship: U.S.

Inventor Two Given Name: Michael
Family Name: Gough
Name Suffix:
Postal Address Line One: 428 6 Street, SW
Postal Address Line Two:
City: Rochester
State/Province: MN
Country: USA
Postal or Zip Code: 55902
City of Residence: Rochester
State/Prov. of Residence: MN
Country of Residence: U.S.
Citizenship: U.S.

Correspondence Information

Palmer & Dodge, LLP
One Beacon Street
Boston, MA 02108
Attention: Kathleen M. Williams

Application Information

Title Line One: Gene Expression by Positive Feedback Activation of a Cell Type-Specific Promoter
Title Line Two:
Total Drawing Sheets: 27
Formal Drawings: N
Application Type: Utility
Docket Number: 18093/1170
Licensed – US Government Agency: No

Secrecy Order in Parent Application: No

Dianne M. Rees
Palmer & Dodge LLP
One Beacon Street
Boston, MA 02108

This application claims priority under 35 U.S.C. § 119(e) to
 >Application One: 60/167,085
 Filing Date: November 22, 2000

[illegible]

5 **GENE EXPRESSION BY POSITIVE FEEDBACK ACTIVATION OF A CELL TYPE-
SPECIFIC PROMOTER**

Related Applications

10 This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application
Serial No. 60/167,085, filed November 23, 1999, the entirety of which is incorporated by
reference herein.

Field of the Invention

15 The invention is related to the area of gene therapy. In particular, the invention is related
to vectors comprising cell type-specific promoter elements that selectively express cytotoxic
genes in tumor cells.

Background of the Invention

20 A major unresolved problem in the field of gene therapy is how to achieve the expression
of a therapeutic gene in target cells where its effects are desired while avoiding its expression in
non-target cells. The problem is especially acute when the transgene has the capacity to harm
non-tumor cells and tissues, for example, where a suicide gene is used to destroy a tumor. Two
basic approaches have been attempted: the transgene can be delivered in the form of a vector
targeted specifically to certain types of cells (vector targeting; see, e.g., Peng and Russell, Cur.
Opin. Biotech. 10: 454-457 (1999)) or the transgene can be cloned downstream of a cell type-
specific promoter (transcriptional targeting; see Vile, et al, Mol. Med. Today 4: 84-92 (1998)).
25 Targeting of vectors can also rely on physically administering them to a particular anatomical
location, either by relying on the natural tropisms of the vectors or by engineering them to

recognize a molecular target. A combination of these approaches offers the best hope for the systemic delivery of vectors to treat human disease. Vile, et al., *supra*.

A variety of cell type-specific promoters are known. Examples include promoters for tyrosinase (specific for melanoma cells and melanocytes; see, Bentley, et al, Mol. Cell. Biol. 14: 7996-8006 (1994)), carcinoembryonic antigen (CEA, specific for colorectal cancer cells; see, e.g., Schrewe, et al., Mol. Cell. Biol. 10: 2738-2748 (1990)), alpha fetoprotein (specific for hepatocytes; see, e.g., Ghebranious, et al., Mol. Reprod. Dev. 42: 1-6 (1995)), erb-B2 (specific for breast cancer cells; see, e.g., Pandha, et al., J. Clin. Oncol. 17: 2180 (1999)) and myelin basic protein (specific for glioma cells; see, e.g., Shinoura, et al., Cancer Res. 59: 5521-5528 (1999)).

However, the use of cell type-specific promoters to induce the expression of cytotoxic agents in tumor cells is particularly problematic. The higher the potency of the suicide gene applied (e.g., toxicity), the greater the potential damage to non-tumor cells that receive the gene if the promoter controlling the suicide gene is not perfectly tumor-specific. Further, inadequate promoter specificity can have serious deleterious effects in non-target cells and tissues which are only revealed under certain conditions. For example, previous work has demonstrated that three tandem repeats of an enhancer element from the human tyrosinase gene (the tyrosinase distal element, TDE), when combined with a basal SV40 promoter, is sufficient to support highly selective expression of the cytokine GM-CSF in human melanoma cells (Diaz et al. J. Virol. 72: 789-95 (1998)). However, when the TDE-SV40 promoter is used to drive the expression of the envelope glycoprotein from Gibbon Ape Leukemia Virus (GALV), a highly cytotoxic fusogenic membrane glycoprotein (FMG), 3 of 9 *non*-melanoma cell lines showed significant amounts of cell killing (syncytium formation) after 72-96 hours, indicating that for this construct the TDE-SV40 promoter was not completely cell type-specific. Therefore, the high toxicity of proteins like GALV envelope glycoprotein, which makes them desirable as potent antitumor agents, will result in an unacceptable amount of bystander killing (killing of nearby normal cells) unless the expression of such agents can be made highly specific for their target cells.

While these problems can be overcome by developing promoters with higher specificity, high tissue specificity tends to be achieved at the expense of promoter strength, thereby undercutting the potency of the therapeutic gene.

Summary Of The Invention

It is an object of the invention to provide methods and materials to selectively express transgenes in a target tissue. It is also an object of the invention to provide methods and materials to amplify the activity of a cell type-specific promoter. It is another object of the invention to provide methods and materials using a cell type-specific promoter that controls expression of a cytotoxic gene, thereby enhancing the selective killing of targeted cells.

The invention further provides a new class of genes with both direct cytotoxic and immunostimulatory properties. It is still another object of the invention to provide materials such as cell type-specific promoters and constructs containing them. A further object of the invention is to provide targeted expression vectors comprising cell type-specific promoters. These and other objects of the invention are provided by one or more of the embodiments described below.

One embodiment of the invention provides a nucleic acid molecule comprising an amplification promoter element (e.g., a heat shock element), a cell type-specific promoter, and a cytotoxic gene under control of the cell type-specific promoter. The nucleic acid molecule can optionally comprise a sequence encoding a amplification promoter transcription activator (e.g., HSF-1 or a constitutively active mutant thereof), that activates the amplification promoter element. For some embodiments, when the nucleic acid molecule is expressed in a target tissue, the level of mRNA expression from the construct is at least 100-fold higher or at least 1000-fold higher than if the construct is expressed in a non-target tissue.

Another embodiment of the invention provides a human tyrosinase promoter and a cytotoxic gene under control of the promoter. In one embodiment, the promoter is Tyr300.

A further embodiment of the invention provides a nucleic acid construct for positive feedback amplification of the expression of a transgene. The construct comprises a heat shock element, a promoter that controls expression of the transgene, and a sequence encoding a transcriptional activator. The transcriptional activator activates the heat shock element to increase the activity of the promoter, resulting in greater expression of the transgene and the sequence encoding the transcriptional activator. In one embodiment, the transcriptional activator

can be HSF-1 or a constitutively active mutant of HSF-1. In another embodiment, the promoter is a cell type-specific promoter.

Still another embodiment provides a vector comprising a heat shock element, a cell type-specific promoter, and a cytotoxic gene under control of the cell type-specific promoter.

5 A further embodiment provides a pair of vectors. The first vector comprises a heat shock element, a cell type-specific promoter, and a cytotoxic gene under control of the cell type-specific promoter. The second vector comprises a sequence encoding a transcriptional activator that activates the heat shock element (e.g., such as HSF-1).

10 Yet another embodiment provides a method of treating a patient in need of tissue-selective gene therapy. In this embodiment, a vector comprising a heat shock element, a cell type-specific promoter, and a cytotoxic gene under control of the cell type-specific promoter is administered to the patient.

Another embodiment provides a method of treating a patient in need of targeted cytotoxic gene therapy. An effective amount of a vector is administered to the patient. The vector
15 comprises a nucleic acid molecule comprising an enhancer, a target cell type-specific promoter, a cytotoxic gene under control of the target cell type-specific promoter, and a gene encoding a transcription factor that activates the enhancer.

Still another embodiment provides a method of specifically inducing expression of a transgene in a melanoma cell. The melanoma cell is transfected with a vector comprising a
20 Tyr300 promoter and a transgene. The production of transgene mRNA is at least 100-fold higher in the melanoma cell than in non-melanoma cells.

The invention thus provides new tools and methods for the highly selective expression of transgenes in a desired target tissue.

Brief Description of the Drawings

25 The objects and features of the invention can be better understood with reference to the following detailed description and accompanying drawings.

Figure 1 is a schematic diagram of a nucleic acid construct for the selective expression of a transgene in a target cell according to one embodiment of the invention. "HSE" refs to a heat shock element. The dashed line indicates that the sequence encoding a HSE activator can be optionally included in the same construct with the transgene or in a separate construct.

5 Figure 2 shows the results of RT-PCR to detect expression from CMV promoters (odd numbered lanes) or TDE-SV40 (even numbered lanes; SV40: Simian Virus 40) in non-melanoma cells (HT1080, 293, Tel.CeB6 or Hela cells, as indicated) and melanoma cells (B16 or A378M). Equal loading was verified with a GAPDH control (not shown).

10 Figures 3A and 3B illustrate the high selectivity of a human tyrosinase 300 base pair (base pair) promoter element using a nested RT-PCR assay. Figure 3A indicates that the Tyr 115 base pair promoter is not completely inactive in non-melanoma cells. RT-PCR to determine expression of the CAT gene under the control of the Tyr11 base pair promoter was performed using RNA from a range of non-melanoma lines (lanes 2 and 3, HT1080; lanes 4 and 5, 293; lanes 12 and 13, A378M). Reverse transcriptase was omitted in the odd numbered lanes.
15 Expression is observed in at least 2 non-melanoma cell lines (293, lane 4 and Tel CeB6, lane 6). Figure 3b shows the same RT-PCR assay of Figure 3A repeated to determine the expression of a CAT gene under the control of the Tyr300 promoter. Lane assignments are the same as those in Figure 3A.

20 Figure 4 demonstrates that HSE confers heat-shock and mHSF-1 inducibility on the melanoma-specific Tyr 300 base pair promoter. MeWo cells transfected with the Tyr 300-GM-CSF (condition 2) or the HSE-Tyr300-FULL-GM-CSF plasmids (condition 6) express only very low amounts of GM-CSF, demonstrating that Tyr 300 is a very weak promoter. However, transfection of the human melanoma MeWo line with the TDE-SV40-GM-CSF plasmid (condition 3) leads to easily detectable levels of GM-CSF production. In the presence of either
25 heat shock (e.g., 42°C, 30 minutes, condition 4) or a co-transfected mHSF-1 plasmid (condition 5), GM-CSF production is increased significantly following transfection with the HSE-Tyr300-GM-CSF plasmid. Co-transfection of a non-melanoma cell line (HT1080) with the HSE-Tyr 300-GM-CSF plasmid and the HSF-1 cDNA did not yield any detectable GM-CSF production (condition 1).

Figure 4 demonstrates that HSE confers heat-shock and mHSF-1 inducibility on the melanoma-specific Tyr 300 base pair promoter. MeWo cells transfected with the Tyr 300-GM-CSF (condition 2) or the HSE-Tyr 300-FULL-GM-CSF plasmids (condition 6) express only very low amounts of GM-CSF, demonstrating that Tyr 300 is a very weak promoter. However, transfection of the human melanoma MeWo line with the TDE-5V40-GM-CSF plasmid (condition 3) leads to easily detectable levels of GM-CSF production. In the presence of either heat shock (42 °C, 30 minutes; condition 4) or a co-transfected mHSF-1 plasmid (condition 5), GM-CSF production is increased significantly following transfection with the HSE-Tyr 300-GM-CSF plasmid. Co-transfection of a non-melanoma cell line (HT1080) with the HSE-Tyr 300-GM-CSF plasmid and the HSF-1 cDNA did not yield any detectable GM-CSF production (condition 1).

Figure 5 demonstrates hsp70 expression following transient transfection of murine melanoma cells with mutant HSF-1. An immunoblot is shown for Hsp70 expression in B16 cells stably expressing constitutively active human mHSF-1 (deletion 202-316). Lysates of untransfected B-16 cells are shown in lane 1. Lane 2 shows the pooled population of HSF-1 transfected colonies. Lanes 3-7 show clones of individual HSF-1 transfected colonies.

Figure 6 displays a portion of an expression vector in which an HSE transcriptional control element can be used to transactivate gene expression from the melanoma-specific Tyr-300 promoter. (FMG: fusogenic membrane glycoprotein; IRES: internal ribosomal entry site).

Figures 7A - 7D demonstrate the elimination of primary tumors by plasmids containing cell type-specific promoter elements. See Example 4 for details. Figure 7A. Tumor size is presented seven days following injection of CMV- β -Gal, CMV-GALV, or Tyr300-GALV plasmid DNA (10 ug/tumor) into HT1080 tumors in nude mice. Figure 7B. Same group of mice as in Figure 7A at 13 days post transduction. Figure 7C. Same group of mice as in Figure 7A at 30 days post transduction. Figure 7D. Size of Me1624 tumors (human melanoma) grown in nude mice at 30 days after injection with CMV- β -Gal, CMV-GALV, or Tyr300-GALV plasmids.

Figure 8 shows the results of RT-PCR experiments to determine expression of a transgene (GALV) from the CMV (odd numbered lanes) or TDE-SV40 (even numbered lanes)

promoters in non-melanoma (HT1080, 293, Tel.CeB6 or Hela cells, lanes 1-8) and melanoma cells (B16 and A378M, lanes 9-12). Equal loading was verified with a GAPDH control (data not shown).

Figures 9A-B illustrate that different elements of the Tyr promoter have different levels of expression in non-melanoma cells. Figure 9A shows the results of RT-PCR performed to determine the expression of the CAT gene directed by the Tyr115 base pair promoter, in a range of non-melanoma (lanes 2-9) and melanoma lines (lanes 10-13). Figure 9B shows the results of a sensitive nested RT-PCR assay to validate the cell type-specific expression of the CAT gene under the control of the Tyr 300 base pair promoter. Lanes are the same as those indicated for Figure 9A. above).

Figures 10A and B illustrate that the HSE element confers heat-shock, and HSF-1d202-316, inducibility on the melanoma-specific Tyr 300 base pair promoter. Figure 10A is a schematic of a nucleic acid construct according to one embodiment of the invention, where the consensus HSE element is cloned upstream of the Tyr-300 promoter element and is separated from the start of the promoter by a linker of either 0 base pair or 10 base pair (i.e., a full turn of the DNA helix) or by 5 base pair (a half turn of the helix). Figure 10B shows the results of a transient transfection assay using the following constructs: Tyr-300-GM-CSF, HSE-Tyr 300-FULL-GM-CSF, TDE-SV40-GM-CSF, HSF-1d202-316 plasmid, and a construct comprising the HSF-1 cDNA.

Figure 11 shows a schematic diagram of a positive feedback loop according to one embodiment of the invention.

Figure 12 shows that the transcriptional feedback loop according to the invention is operative at the transcriptional level. In one embodiment, 5×10^5 murine B16 cells, which are not fused by expression of the GALV FMG, were cotransfected with HSE-Tyr-300-GALV (5 μ g) and mHSF-1(5 μ g). Cells were harvested at time points following transfection as shown and RT-PCR was used to examine levels of expression of the GALV or HSF-1d202-316 transgenes and of endogenous murine hsp70.

Figures 13A-F illustrate that the HSE-Tyr-300/HSF-1 feedback loop can be used to kill melanoma cells specifically and efficiently. Figures 13A and 13B show the effects of control (calcium phosphate only) transfections and transfection with CMV-GALV of non-melanoma TelCeB6 cells. Figures 13C-D show the effects of transfections of Mel624 cells with the HSE-Tyr-300 and Tyr-300-GALV constructs. gave low levels of toxicity when transfected into a melanoma line, (or MeWo, not shown). Figures 13E-F show the effects of transfection with increasing amounts of co-transfected HSF-1d202-316 β -Gal plasmid.

Figures 14A-C show the effects of different vectors on cell type-specific toxicity of a suicide gene in transfected cells, in this embodiment, a cytotoxic fusogenic protein (GALV). Figure 14A is a schematic diagram showing the construction of the pBabe-GALV-HSF-1 (HSE-Tyr LTR) vector, pBabe Puro (no GALV nor HSF-1 cDNAs); pBabe-GALV-HSF-1 (wtLTR), pBabe-GALV-HSF-1 (HSE-Tyr LTR), and pBabe-GALV - pBabe Puro vectors. Figure 14B shows the time course of syncytial development in a melanoma cell line (Mel624) and a non-melanoma cell line (TelCeB6) following infection with viral stocks. The development of syncytia within the cultures was followed at time points following infection ($t=0$). Syncytia were scored depending upon the proportion of cells in random fields that were within syncytia: -, no visible syncytia; +, 0-20% ; ++, 20-40%; +++40-60%; ++++60-80%; +++++80-100%. Figure 14C shows the cytotoxicity of the viral vectors of Figure 14A. At $t=120$ hrs following infection in the experiment depicted in Figure 14B above, the total number of surviving cells were counted by trypan blue exclusion.

Description

Tissue specific promoters enable a higher degree of expression of a transgene in certain cells where the transgene product is desired, i.e., in target cells vs. non-target cells. However, in some applications, for example, such as, the delivery of cytotoxic genes to tumor cells, even a low level of expression in non-target cells can be undesirable. The invention provides methods and materials that permit highly selective expression of transgenes in a desired tissue or cell type with little or no expression in non-target cells and tissues. The methods of the invention are useful in the treatment of cancer, genetic disease, and other ailments amenable to gene therapy.

The invention is especially useful where selective expression of a transgene in specific target cells with minimal expression in non-target cells is desired for therapeutic or research purposes.

Definitions

In order to more clearly and concisely describe and point out the subject matter of the claimed invention, the following definitions are provided for specific terms which are used in the following written description and the appended claims.

As used herein, the term “nucleic acid molecule” refers to any natural or synthetic nucleic acid, e.g., DNA, RNA, and chemical analogs and derivatives thereof, either single-stranded, or double-stranded, that is capable of encoding an amino acid sequence and serving as a template for synthesis of a polypeptide. As used herein, the term “nucleic acid molecule” encompasses nucleic acid constructs, cassettes, and vectors.

A “nucleic acid construct,” “construct,” or “cassette” is a nucleic acid molecule which has been assembled from precursor nucleic acid molecules to form a single nucleic acid molecule with a plurality of functions, e.g., a sequence functioning as a promoter plus a sequence functioning to encode a therapeutic gene. As used herein, the term “construct” encompasses the term “vector.”

A “vector” is a nucleic acid molecule which is suitable for introduction of a nucleic acid construct or transgene into a target cell by transfection or transformation. Vectors of the invention include, but are not limited to, any plasmid vector or viral vector known in the art.

A “target cell” is any cell which is the preferred or intended recipient of a nucleic acid construct or transgene which can be delivered either *in vivo* or *ex vivo*, including human cells.

A “transgene” is any nucleic acid sequence that encodes a polypeptide for expression in a target cell.

A “therapeutic transgene” is a transgene encoding a protein which achieves a therapeutic effect when expressed in a cell. A “therapeutic effect” is an effect which ameliorates the symptoms of a disease or which restores molecular parameters to normal levels, i.e., restoring the expression of genes and/or proteins and/or other biomolecules to a level found in individuals

who do not have the disease. For example, in one embodiment, the therapeutic effect in a patient with prostate cancer is the restoration of PSA levels to within normal levels (no significant difference determined between levels of PSA in the patient with prostate cancer compared to a patient without prostate cancer, as determined by routine statistical testing to within 95% confidence levels).

A “cytotoxic gene” is any nucleic acid sequence that leads to the death of a cell in which it is expressed within a period of 1, 2, 3, 5, 7, 10, 14, 21, 30, 60, or 100 days.

A “cell type-specific” promoter, promoter element, enhancer, or enhancer element according to the invention is one which leads to a higher degree of expression of a gene under its control in a target cell of the cell type in which the promoter is active than in a non-target cell of cell type in which the promoter is substantially inactive. A promoter, promoter, promoter element, enhancer, or enhancer element, is preferably highly cell-type specific, in which case, the “specificity of expression” of the gene under their control is at least 5-fold, 7-fold, 8-, 9-, 10-, 20-, 30-, 50- 100-, 300-, 1000-, 3000-, 10,000-, 30,000-, or 100,000- fold higher in a specific cell type/target cells than in non-target cells. Since non-target cells may differ with respect to expression of a given promoter, promoter element, enhancer, or enhancer element, an average of the expression in at least five different non-target cell types should be compared with the expression in target cells to determine the specificity of expression. A cell type-specific promoter encompasses both tissue-specific promoters and tumor-specific promoters. In one embodiment, the cell-type specific promoter is both tissue-specific and tumor-specific.

As used herein, the terms “promoter element” refers to a subsequence of a promoter that binds to a transcriptional activator. As used herein, the term “promoter element” encompasses enhancer sequences.

An “enhancer” is a sequence which enhances transcription of a promoter and which can be placed in any orientation with respect to the promoter and can function upstream or downstream of a gene, to enhance transcription.

A defined herein, “operably linked” refers to a promoter sequence or promoter element or enhancer which is in sufficient proximity to the transcription start site of a gene to regulate transcription of the gene.

An “amplification promoter element” refers to a sequence, which activates transcription of an operably linked sequence in the presence of an amplification promoter transcription activator. In one embodiment, an amplification promoter element is a heat shock element (HSE) activateable by a “heat shock activator”. A heat shock activator is a transcription activator which is expressed or activated when a cell is exposed to heat or other environmental stressors.

A “transcription activator” is a biomolecule (e.g., protein, polypeptide, nucleic acid sequence, and the like) which binds to a promoter element and enhances transcription of an operably linked gene as compared to the transcription of the gene in the absence of the transcription activator.

Cell Type-Specific Promoters

In one embodiment of the invention, highly cell type-specific promoters are screened for to drive the expression of a therapeutic transgene in a target cell of interest (e.g., a specific tissue or tumor cell). In one embodiment, the cell type-specific promoter is identified by validating that the cell-type specificity of a known cell type-specific promoter when cloned upstream of a therapeutic transgene provides expression of the transgene at levels which are 5-fold, 7-fold, 8-, 9- fold, 10- fold, 20- fold, 30-fold, 50- fold, 100- fold, 300- fold, 500-fold, 1000- fold, 3000-fold, 10,000- fold, 30,000- fold, or 100,000- fold higher in the specific cell type (e.g., the target cell) than in cells which are other than the specific cell type (e.g., non-target cells), after evaluating gene expression in at least six different types of cells or tissue types. In one embodiment, a highly cell type-specific promoter is identified which is expressed in only one of the at least six tissues examined. In another embodiment, the cell type specific promoter provides expression of the transgene at levels which are at least 100-fold, at least 500-fold, or at least 100-fold higher in the specific cell type than in cells which are other than the specific cell type.

In another embodiment of the invention, novel or uncharacterized sequences are screened to identify highly cell type-specific promoter sequences. In another embodiment, minimal promoter sequences are identified, e.g., the minimum length of sequence necessary and sufficient to drive highly cell type-specific expression of a transgene in amounts necessary to achieve a therapeutic effect.

Identification of Known Cell Type-Specific Promoters

In one embodiment of the invention, selective expression of a therapeutic transgene for delivery into a cell (either *in vivo* or *ex vivo*) is achieved by placing the transgene under control of a highly cell type-specific promoter, which is identified by searching the published literature and/or sequence databases. In one embodiment, the cell type - specific promoter is a tissue-specific promoter. Examples of promoters with high tissue specificity that have been reported include, but are not limited to, the promoters for tyrosinase (specific for melanoma cells and melanocytes; Bentley, et al. Mol. Cell. Biol. 14: 7996-8006 (1994)), carcinoembryonic antigen (CEA, specific for colorectal cancer cells; Schrewe, et al. Mol. Cell. Biol. 10: 2738-2748 (1990)), alpha fetoprotein (hepatocytes; Ghebranious, et al. Mol. Reprod. Dev; 42: 1-6 (1995)), erb-B2 (breast cancer; Pandha, et al., J. Clin. Oncol. 17: 2180(1999)), and myelin basic protein (glioma cells; see Shinoura, et al. Cancer Res. 59: 5521-5528 (1999)).

Additional examples of cell type-specific promoters include, but are not limited to, α -S1- and β -casein promoters which are specific for mammary tissue (Platenburg, et al., Trans. Res. 3: 99-108 (1994); Maga, et al., Trans. Res. 3: 36-42 (1994)); the phosphoenolpyruvate carboxykinase promoter, which is active in liver, kidney, adipose, jejunum and mammary tissue (McGrane, et al., J. Reprod. Fert. 41: 17-23 (1990)); the involucrin promoter, which is only active in differentiating keratinocytes of squamous epithelium (Carroll, et al., J. Cell Sci. 103: 925-930 (1992)); and the uteroglobin promoter, which is active in lung and endometrium (Helftenbein, et al., Annal. N.Y. Acad. Sci. 622: 69-79(1991)).

The near completion of the human genome project has resulted in sequence data relating to the structure of many additional cell type-specific promoters being available to the public. In one embodiment, therefor, a cell type-specific promoter sequence to be used in generating a construct according to the invention is obtained from a database such as the Eukaryotic Promoter

Database (EPD) (<http://www.epd.isb-sib.ch/>). The sequences included within this database (and other sequence databases) and which are added to these databases are encompassed within the scope of the invention.

In certain embodiments of the invention, the highly cell type-specific promoter is a tumor-specific promoter which drives the expression of the transgene in tumor cells but does not significantly express the transgene in non-tumor cells. In a preferred embodiment, a highly tumor-specific promoter expresses a transgene to which it is operably linked greater than 100-fold, greater than 500-fold, or greater than 1000-fold in tumor cells compared to non-tumor cells. Tumor-specific promoters encompassed within the scope of the invention include, but are not limited to, promoters which control the expression of prostate specific antigen or PSA (Osterling, J. Urol. 145: 907-923 (1991)), epithelial membrane antigen, expressed in multiple epithelial carcinomas (Pinkus, et al.; Am. J. Clin. Pathol. 85: 269-277 (1986)), CFYRA 21-1, expressed in lung cancer (Lai, et al., Jpn. J. Clin. Oncol. 29: 421 (1999)) and Ep-Cam, expressed in pan-carcinoma cells (Chaubal, et al., Anticancer Research 19: 2237-2242 (1999)). The entireties of these references are incorporated by reference herein.

Identification of New Cell Type-Specific Promoter Sequences

Elements of promoters or enhancers can be identified which will selectively drive the expression of a transgene in a desired target cell using methods which are standard in the art. For example, in one embodiment, a gene is identified which is expressed in a cell type-specific manner by obtaining a subsequence of the gene (or cDNA) for use as a probe or primer (e.g., from a genomic or cDNA library), and determining whether the gene is expressed in one or a few cell types (e.g., one or a few tissues and/or tumor types). In one embodiment, the subsequence is used as a probe and its hybridization to RNA or cDNA obtained from one cell type, and lack of hybridization in at least five other cell types, is used to identify the gene as one whose expression is cell type-specific. In another embodiment, cell type-specificity of a promoter is determined by monitoring the expression of the protein product of the gene, for example, by immunoassay, or any other protein detection method. In one embodiment, tissues are obtained from patients, from autopsy specimens, or from commercially available sources (e.g., such as Clontech's "Tissue Northern"). In another embodiment of the invention, tumor-specific promoters are identified by

examining the expression of the protein product in tumor cell lines, biopsy samples, and other sources of tumor tissue, and comparing this expression to the expression in non-tumor cells.

Having identified a gene expressed in a cell type-specific manner, a cell type-specific or tumor-specific promoter sequence from this gene is then identified from genomic clone(s) and the ability of the promoter sequence to drive the expression of a transgene in a cell type-specific manner is determined.

Defining Minimal Promoter Sequences

Methods of identifying promoter sequences are routine in the art. For example, in one embodiment of the invention, to identify a promoter sequence, the 5' portion of a gene is analyzed for the presence of sequences characteristic of promoter sequences, such as a TATA box consensus sequence (TATAAT), which is usually an AT-rich stretch of 5-10 base pair located approximately 20 to 40 base pair upstream of the transcription start site. In one embodiment, the location of a TATA box is determined using standard RNA-mapping techniques such as primer extension, S1 analysis, and/or RNase protection, to identify the position of the transcription start site within a genomic clone, and the TATA box is identified, either visually, or using a sequence search program. For example, sites important in transcriptional activation can be identified using the publically available sequence search program TF SEARCH (<http://www.genome.ad.jp/SIT/TFSEARCH>). Another publically available database of sequences to which transcription factors bind is available from the National Library of Medicine in the "Transcription Data Base."

To define a minimal cell type-specific promoter sequence, sequences upstream of the transcription start site are fused to a reporter gene (e.g., beta-galactosidase, luciferase, chloramphenicol acetyltransferase or CAT, green fluorescent protein or GFP, and the like) in order to determine which sequences are both necessary and sufficient to drive expression of the reporter gene. If sequences are identified which contain the necessary sequences for cell-type specific expression (e.g., tissue-specific and/or tumor-specific), deletions can be made in the 5' flanking sequences of a genomic clone to determine which sequences are minimally required for tissue-type specific expression. This can be performed *ex vivo*, first, by examining the expression of the reporter gene operably linked to the flanking sequences in cell type-specific

culture cells, with comparison to expression in non-cell type-specific culture cells, e.g., using primary cell lines obtained from different tissue types or continuous cell lines known to express the properties of specific tissue types, or tumor cell types (such as obtainable from the American Type Culture Collection ATCC®; Manassas, VA; <http://wssw.atcc.org>).

5 In one embodiment, to verify that a nucleic acid molecule (e.g., construct and/or vector) is successfully expressing a desired transgene in a cell type-specific manner *in vivo*, the cell type-specific promoter is cloned upstream of the transgene of interest and the transgene is introduced into a mammal (e.g., a mouse, such as the C57BL/6J strain, or a rat) using standard techniques (see, e.g., "Manipulating the Mouse Embryo" by Brigid Hogan, Frank Costantini and Elizabeth
10 Lacy, Cold spring Harbor Laboratory, Cold Spring Harbor, N.Y., the entirety of which is incorporated herein by reference). In one embodiment, the nucleic acid molecule, construct, or vector is introduced into the pronucleus of fertilized mouse oocytes according to standard procedures.

For example, in one embodiment, mouse zygotes are collected from six week old
15 C57B/6J females (Jackson Laboratory, Bar Harbor, Me.) that have been superovulated with 5 IU of Pregnant Mare's Serum Gonadotropin followed 48 hours later by 50 U Human Chorionic Gonadotropin. Primed females are placed with C57BL/6J males and checked for vaginal plugs the following morning. Pseudopregnant females, used as recipients, are selected for estrus and placed with proven sterile vasectomized males.

20 Zygotes are collected (e.g., in BMOC-2 medium modified to contain 5.1 g/l NaCl and 5 mg/ml bovine serum albumin) and cumulus cells are removed by treatment with hyaluronidase (e.g., Sigma Type IV, 300 IU/ml PBS with 1% PVP 40T, Sigma) diluted to 60 IU/ml in culture medium. Zygotes are washed several times in culture medium to remove debris. Approximately 2 pl of DNA solution (1-2ng DNA/ μ l of buffer) is injected into zygotes which are incubated in
25 5% CO₂ in air at 37° C until transferred to the oviduct of recipient females under a suitable anaesthesia (see, e.g., as described in Brinster, et al., Proc. Natl. Acad. Sci. USA 82: 4438 (1985), the entirety of which is incorporated herein by reference). While injection can be done in fertilized oocytes, transgenic animals can be obtained from injected two-cell embryos.

Transferred oocytes/embryos are allowed to differentiate and develop within the recipient females.

Increased efficiency of integration into the genome can be achieved by linearizing the nucleic acid molecule prior to injection, and by injection into the male or female pronucleus of the oocyte rather than the cytoplasm. The strain of mouse can also be optimized to enhance efficiency of integration. For example, in addition to C57BL6 mice, hybrid C57 x SJL mice or CD-1 mice can also be used.

Transgenic founder mice carrying single copies of the therapeutic transgene under the control of a highly cell type-specific promoter are screened and selected by analyzing a source of genomic DNA (e.g., a section of tail or ear). In one embodiment, the therapeutic transgene is injected into the oocyte/embryo of a mouse null for the therapeutic transgene, in which case, the copy number and structure of the transgene which is integrated into the genome is analyzed by hybridization with nucleic acids from the transgene to determine whether any rearrangement or modification has occurred in the transgene during the integration process. However, when a null background is not used, the presence and structure of a reporter gene which is part of the same molecule as the therapeutic transgene is ascertained. Only mice carrying single copies of the complete transgene/reporter gene are selected for analysis of cell type-specific gene expression. In one embodiment, both the therapeutic transgene and reporter gene are operably linked to the same cell type-specific promoter.

Transgenic founder mice (e.g., expressing a marker gene cloned on the same molecule as the therapeutic transgene) are analyzed using any known assay to either quantitatively or semi-quantitatively indicate the level of expression of the transgene in target cells or tissue compared with non-target cells or tissue. For example, reverse transcriptase polymerase chain reaction (RT-PCR) can be used to quantify the amount of mRNA produced by a target cell after delivery of the transgenes (see, e.g., Vile, et al., Virology 214: 307-313 (1995)). Alternatively, a reporter gene can be included in the nucleic acid molecule, construct, or vector, and the reporter gene product can be quantified using available techniques such as immunoassay, fluorescence, spectroscopy, and the like.

In one embodiment, appropriate tissues are collected at autopsy from transgenic mice to assay for expression of the therapeutic transgene and/or reporter gene. RNA and/or protein are extracted from these tissues and used in hybridization assays and/or immunoassays to detect expression of transgene/reporter mRNA and/or protein. In one embodiment, tissues are selected from brain, skin, liver, spleen, kidney, heart, lung, gonad, uterus, pancreas, fundus of the stomach, duodenum, ileum, colon and sternal bone marrow to perform RT-PCR, *in situ* hybridization and/or immunohistochemistry.

The specificity of expression of a transgene under the control of a cell type-specific promoter can be evaluated by comparing expression of the transgene using any of the above methods in a target cell (e.g., the specific cell type) with the expression in non-target cells. Since non-target cells may differ with respect to expression of a given promoter or enhancer, in one embodiment, an average of the expression in at least five different non-target cell types is compared with the expression in target cells to determine the specificity of expression.

Melanoma-Specific Promoters

In one embodiment, the invention comprises nucleic acid constructs in which the cell type-specific promoter controlling the expression of the therapeutic transgene is the minimal melanoma-specific promoter of 300 base pair corresponding to bases -300 to -1 of the human tyrosinase gene ("Tyr300"; SEQ ID NO: 1):

(-300)	tcatttgcaa	ggc caaatca	tcattagttt	tgtagtctat
	taactggggt	tgcttaggtc	aggcattatt	attactaacc
	ttattgttaa	tattctaacc	ataagaatta	aactattaat
	ggtgaataga	gtttttcact	ttaacatagg	cctatcccac
	tggtgggata	cgagccaatt	cgaaagaaaa	gtcagtcatg
	tgcttttcag	aggatgaaag	cttaagataa	agactaaaag
	tgtttgatgc	tggaggtggg	agtgggtatta	tataggtctc
	agccaagaca	tgtgataatc (-1)		

Tyr300 is a subsequence of the 5' untranslated region of the human tyrosinase gene whose sequence was previously described by Bentley, et al., Mol. Cell. Biol. 14:7996-8006 (1994), the entirety of which is incorporated by reference herein. The 300 base pair element of the human tyrosinase promoter contains at least four positive DNA binding elements as well as one negative element as described by Bentley et al., *supra*. Of particular importance is the M box (at -107 to -97), a conserved element found in other melanocyte-specific promoters (Bentley, et al., *supra*).

In one embodiment, Tyr300 is incorporated into a recombinant construct where it functions as a highly selective activator for transgene expression in melanoma cells (see Example 1).

Other melanoma-associated polypeptides are known and their genes can be screened to identify the presence of melanoma-specific promoters, as described above. These polypeptides are described in, for example, Kupsch, et al., Hum. Gene Ther. 9: 737-746 (1998); Neri, et al., J. Invest. Dermatol. 107: 164-170 (1996); and Kirkin, et al., Exp. Clin. Immunogen. 15: 19-32, (1998), the entireties of which are incorporated by reference herein.

Amplification of Cell Type-specific Promoter Activity

In selecting for promoter elements with high cell type-specificity, the inventors discovered that the such promoters tend to be weaker than promoters which mediate less selective expression of downstream sequences, i.e., cell type-specificity is achieved at the expense of promoter strength. Therefore, in one embodiment, methods and materials with which to drive tissue-selective expression of transgenes using a positive feedback mechanism are provided.

In one embodiment according to the invention, an amplification promoter element, such as a heat shock element is used to amplify the expression of a downstream therapeutic transgene. Heat shock elements ("HSEs") are sequences found within the first 100 base pair 5' of the RNA start site of eucaryotic heat shock genes (see, e.g., Sorger, P. K. Cell 65: 363 (1991), the entirety of which is incorporated by reference herein). Heat shock genes, such as Hsp70 genes, from different species differ in the number and orientation of HSEs and in the types of other transcription factor-binding sites found upstream. HSEs include the sequence nGAAn, repeated

at least two times in head-to-head or tail-to-tail orientation (nGAAnnTTCn or nTTCnnGAAn), and in one embodiment of the invention, the HSE comprises at least two nGAAn sequences.

An HSE functions in stress-induced promoter activation by binding a positive transactivating factor, the heat shock factor (HSF-1). The binding constant of this factor to the heat shock element is about a hundred-fold higher than that of any other known mammalian transcription factor to its respective binding site, rendering it a very strong promoter element. The present invention provides a strategy to amplify the expression of a transgene by providing at least one upstream HSE, responsive to an HSF. This strategy can be applied to augment the activity of any promoter and consequently boost the expression of any transgene.

HSE is inducible by HSF-1 in the presence of environmental stressors such as heat, anoxia, or ethanol. Therefore, in one embodiment, a target cell is exposed to heat during and/or prior to, and/or after delivery of a therapeutic transgene whose expression is mediated by an HSE element activated by an HSF-1. Heat activates the HSF-1 protein and allows it to enter the nucleus and bind HSE. In one embodiment, "exposing the target cell to heat" comprises elevating the temperature of the target cell, either by localized heating, e.g., that which may be produced by a focused microwave beam, or by generalized heating, e.g., by a temperature bath. In one embodiment of the invention, the production of the therapeutic transgene's product is enhanced by increasing the ambient temperature of the cells to which is has been/ or is being delivered, to a temperature above 37° C. In another embodiment, cells are maintained at a temperature of 38 to 45° C., more preferably 39 to 44° C, and most preferably 40 to 43° C., for a period of 1 to 12 hours, more preferably 4 to 6 hours, and most preferably 6 hours. In another embodiment, the temperature is elevated periodically, i.e., for 1 to 10 hours a day, more preferably 3 to 6 hours a day, for a period of 1 to 21 days or more.

Other suitable temperatures and time periods can be readily determined by one of skill in the art to optimize the efficiency of the HSE, thereby maximizing production levels of a desired therapeutic transgene product. The induction of HSE's in human cells is described further in Ritossa, *Experientia* (Basel) 18: 571 (1962); Nover, *Heat Shock of Eukaryotic Cells* Springer, Berlin (1984); Craig, *CRC Cit. Rev. Biochem.* 18: 239 (1985); Pelham, *Trends Genet.* 1: 31 (1985); Lindquist, *Ann. Rev. Biochem.* 55: 1151 (1986); Pelham, et al., *EMBO J.*, 1: 1473

(1982); Mirault, et al., EMBO J. 1: 1279 (1982); Wu, et al., Mol. Cell. Biol. 5: 330 (1985); Voellmy, et al., Proc. Natl. Acad. Sci. USA 82: 4949 (1985); Drabent, et al., Nucl. Acids Res. 14: 8933 (1986); Berger, et al., Somat. Cell. Molec. Genet. 12: 433 (1986); Wu, et al., Proc. Natl. Acad. Sci. USA 83: 629 (1986), for example, the entireties of which are incorporated
5 herein by reference.

Chemical agents can also be used to induce the HSE, e.g., through their interactions with HSF-1 (see, e.g., as described in U.S. Patent No. 5,137,805, the entirety of which is incorporated by reference herein). Activators of HSF-1, such as activating antibodies, polypeptides, and peptide fragments, or aptamers, can be introduced by providing their sequences along with those
10 of the therapeutic transgene and the HSF-1, or by administering the activator directly to the patient (e.g., intravenously, intramuscularly, subcutaneously, enterally, or parenterally), by continuous infusion, or by single or multiple boluses. This is preferred when the activator is a drug rather than a polypeptide. The activation of the heat shock element by any of the stressors described above provides synergistic immunotherapeutic effects caused by the induction of heat shock proteins (encoded by sequences which also comprise HSE's), which are stimulated by the
15 rise in HSF-1.

Alternatively, a sequence encoding a constitutively active mutant of HSF-1 can be employed (see Example 2), in which case no heat activation step is required. This embodiment may be used where delivery of the transgenes is performed *in vivo* rather than *ex vivo*.

In one embodiment, an HSE sequence is positioned upstream (5' of) a cell type-specific promoter element that regulates the expression of the therapeutic transgene. In another embodiment, multiple HSE sequences are provided. In one embodiment, an HSF-1 sequence is provided as part of a separate nucleic acid construct. In this embodiment, the construct comprising the therapeutic transgene and the construct encoding the HSF-1 protein are provided
20 sequentially, either within minutes or hours of each other; while in a preferred embodiment, the construct comprising the therapeutic transgene and the construct encoding the HSF-1 protein are
25 be delivered to a cell simultaneously, e.g., in the same pharmaceutical excipient.

In another embodiment, the therapeutic transgene and the HSF-1 encoding sequence are part of the same nucleic acid construct and the transcription of both genes is controlled by the

upstream HSE and a cell type-specific promoter. While the low level of promoter activity from the cell type-specific promoter initially supports only a low level of transcription of both transgenes, eventually HSF-1 accumulates to a level which activates the HSE and thereby increases transcription of both the therapeutic transgene and the HSF-1 encoding gene. This positive feedback loop converts a highly specific, but low level of promoter activity, into a highly specific and strong level of promoter activity in a target cell for which the promoter was designed.

A construct which exemplifies this approach is depicted in Figure 6. In this embodiment, a nucleic acid molecule embodying this method comprises: (1) an HSE sequence such as the human consensus sequence 5'-AGAATGTTCTAGAAG-3' (SEQ ID NO:2, *see* Zuo, et al., Mol. Cell. Biol. 15: 4319-4330 (1995)); which is placed upstream of (2) any promoter, and which is followed in a 3' direction by (3) a transgene whose expression is desired, which turn is followed in a 3' direction by (4) a sequence that encodes a transcription factor or transcriptional activator that binds to and activates HSE, such as human heat shock factor-1 (HSF-1). The order of the transgene and the sequence encoding the transcription factor is unimportant; either gene can be positioned near the promoter, as long as transcription of both coding sequences is driven by the promoter. Where HSF-1 is encoded by a sequence not under control of HSE, then simple amplification of expression of the transgene under control of HSE will result.

In another embodiment, an internal ribosomal entry site (IRES) is placed between the therapeutic transgene and the HSF-1 encoding sequence, so that both the product of the therapeutic transgene and the HSF-1 protein are translated from the same message. Internal ribosome entry sites (IRES, also called ribosomal landing pads) are sequences that enable a ribosome to attach to mRNA downstream from the 5' cap region and scan for a downstream AUG start codon, for example in polycistronic mRNA. See generally, Miles, et al., U.S. Patent 5,738,985 and N. Sonenberg and K. Meervitch, Enzyme 44: 278-91 (1990), the entireties of which are incorporated herein by reference. Addition of an IRES between the coding sequences for two transgenes, for example, a cytotoxic gene and a gene encoding HSF-1, can enable the independent translation of either the transgene or HSF-1 from a dicistronic or polycistronic transcript.

IRES sequences can be obtained from a number of RNA viruses (e.g., picornaviruses, hepatitis A, B, and C viruses, and influenza viruses) and DNA viruses (e.g., adenovirus). IRES sequences have also been reported in mRNAs from eukaryotic cells (Macejak and Sarnow, Nature 353: 90-94 (1991) and Jackson, Nature 353: 14015 (1991)). Viral IRES sequences are detailed in the following publications: (a) Coxsackievirus: Jenkins, J. Gen. Virol. 68: 1835-1848 (1987); Iizuka, et al., Virology 156: 64-73 (1987); and Hughes, et al., S. Gen. Virol. 70: 2943-2952; (b) Hepatitis A Virus: Cohen, et al., Proc. Natl. Acad. Sci. USA 84: 2497-2501 (1987); and, Paul, et al., Virus Res. 8: 153-171 (1987); (c) Poliovirus: Racaniello and Baltimore, Proc. Natl. Acad. Sci. USA 78: 4887-4891 (1981); and Stanway, et al., Proc. Natl. Acad. Sci. USA 81: 1539-1543 (1984); (d) Rhinovirus: Deuchler et al., Proc. Natl. Acad. Sci. USA 84: 2605-2609 (1984); Leckie, G., Ph.D. thesis, University of Reading, UK; and Skern, et al., Nucleic Acids Res. 13: 2111 (1985); (e) Bovine enterovirus: Earl et al., J. Gen. Virol. 69: 253-263 (1988); (f) Enterovirus type 70, Ryan, M.D. et al., S. Gen. Virol. 71: 2291-99 (1989); (g) Theiler's murine encephalomyelitis virus: Ohara, et al., Virology 164: 245 (1988); and, Peaver, et al., Virology 161: 1507 (1988); (h) Encephalomyocarditis virus: Palmenberg, et al., Nucl. Acids Res. 12: 2969-2985 (1984); and Bae, et al., Virology 170: 282-287 (1989); (i) Hepatitis C Virus: Inchauspe, et al., Proc. Natl. Acad. Sci. USA 88: 10293 (1991); Okamoto, et al., Virology 188: 331-341 (1992); and Kato, et al., Proc. Natl. Acad. Sci. USA 87: 9524-9528 (1990); and (i) Influenza virus: Fiers, W., et al., Supramol. Struct. Cell Biochem. (Suppl 5): 357 (1981), the entireties of which are incorporated herein by reference.

In other embodiments, other stress inducible promoter elements and stress inducible transcriptional activators, in addition to HSEs and HSFs, respectively, can be used and are encompassed within the scope of the invention. Examples of such types of promoter elements and the activators which regulate them are described in Davis, J. Biol. Chem. 268: 1553 (1993); Holbrook, et al., in: *Stress-Inducible Cellular Responses*, Feige, U., et al., Eds., Birkhauser Verlag (1996); Datta, et al., Proc. Natl. Acad. Sci. USA, 89(21): 10149-10153 (1992); Datta, et al., Proc. Natl. Acad. Sci. USA, 90(6): 2419-2422, (1993); Alexandropoulos, et al., Nucleic Acids Research, 20(9): 2355-2359 (1992); Attar, et al., Molecular and Cellular Biology, 12 (5): 2432-2443, (1992); S. Qureshi, et al., The Journal of Biological Chemistry, 266(17): 10802-10806 (1991); U.S. Patent No. 6,034,228; U.S. Patent No. 5,827,685; and U.S. Patent 5,770,581,

and in U.S. Provisional Application Serial No. 60/193,977, filed March 31, 2000, the entireties of which are incorporated by reference.

As with the HSE-HSF "circuit," the stress-inducible promoter elements described above can be activated by exposing the target cell to the appropriate stressor, which in turn activates the transcription activator, or alternatively, by rendering the expression of the stress-activated transcriptional activator constitutive, e.g., by site-directed or random mutagenesis of the stress activated transcriptional activator and by screening for constitutive activators in cell lines, for example. Amplification promoter elements encompassed generally within the scope of the invention include any promoter element or enhancer sequence responsive to a transcriptional activator which when operably linked to a therapeutic transgene, which in turn is under the control of a highly cell type specific promoter, is capable of driving expression of the transgene at levels suitable for achieving a therapeutic effect.

Transgenes for Use in the Nucleic Acid Constructs

The nucleic acid molecules, constructs, and vectors of the invention can employ any desired transgene for delivery to, and expression in, a target cell. In one embodiment, the transgene encodes for a protein product whose presence is desired in the target cell for therapeutic, investigational, or other purposes. For example, in one embodiment, the transgene encodes a protein which is defective in, or absent from, the target cell because of genetic disease or a pathological condition.

Genes and the diseases associated with them that are appropriate targets for gene therapy using the methods of the invention include, but are not limited to: AGA aspartylglucosaminidase (GenBank Acc. No. X55330), aspartylglucosaminuria; ALDOB aldolase B, fructose-bisphosphate (GenBank Acc. No. X02747), fructose intolerance; BLM Bloom syndrome (GenBank Acc. No. U39817), Bloom syndrome; CFTR cystic fibrosis transmembrane conductance regulator (GenBank Acc. No. S64699), cystic fibrosis; CLCN1 chloride channel 1, skeletal muscle (GenBank Acc. No. Z25884), Thomsen disease; CRH corticotropin releasing hormone (GenBank Acc. No. V00571), ACTH deficiency; DBH dopamine beta-hydroxylase (GenBank Acc. No. X13255), Dopamine-beta-hydroxylase deficiency; F11 coagulation factor XI (plasma thromboplastin antecedent) (GenBank Acc. No. M13 142), Factor XI deficiency; GAA

glucosidase, alpha, acid (GenBank Acc. No.X55079), glycogen storage disease II; GALC galactosylceramidase (GenBank Acc. No. D86181), Krabbe disease; GALT galactose-1-phosphate uridylyltransferase (GenBank Acc. No. M1873 1), galactosemia; HBB hemoglobin, beta (GenBank Acc. No.V00497), sickle cell anemia (beta-thalassemia); HD huntington (GenBank Acc. No. L12392), Huntington disease; FTL ferritin, light polypeptide (GenBank Acc. No. M1 1147), hyperferritinemia-cataract syndrome; MAOA monoamine oxidase A (GenBank Acc. No.M68840), Brunner syndrome; MAT1A methionine adenosyltransferase I, alpha (GenBank Acc. No. D49357), hypermethioninemia; PAH phenylalanine hydroxylase (GenBank Acc. No. U49897), phenylketonuria; PROS 1 protein S (alpha) (GenBank Acc. No. M14338), protein S deficiency; OA1 ocular albinism (GenBank Acc. No. Z48804), Nettlehip-Falls type; SGSH N-sulfoglucosamine sulfohydrolase (sulfamidase) (GenBank Acc. No. NM000199), Sanfilippo syndrome, type A; CCND1 cyclin D1 (PRAD1: parathyroid adenomatosis 1) (GenBank Acc. No. X59798); parathyroid adenomatosis 1, centrocytic lymphoma; DMD dystrophin (GenBank Acc. No. X15149), muscular dystrophy, Duchenne.

Cytotoxic Transgenes Which Provide an Immunostimulatory Component

Gene therapy designed to eradicate tumors has benefited from strategies for simultaneously killing the tumor cells and stimulating the immune response. For example, tumor cell death induced by the HSV thymidine kinase/gancyclovir system also induces hsp70 expression, which in turn induces infiltration of T-cells, macrophages, and dendritic cells, and also increases the expression of cytokines (see, e.g., Todryk, et al., J. Immunol. 163: 1398-1408 (1999)). Infection by replication-competent adenovirus present in adenoviral vectors also induces hsp70 expression and therefore stimulates an immune response to the delivery of cytotoxic transgenes (Melcher, et al., Hum. Gene Ther. 10: 1431-1442 (1999)). Another approach to enhance the immunogenicity of tumors is to provide hsp70 directly to the cells (e.g., by transfecting them with cDNA encoding hsp 70 as described in Melcher, et al., Nat. Med. 4: 581-587 (1998), for example). The entireties of these references are incorporated herein by reference.

In one embodiment, a transgene for use with the invention is a cytotoxic gene or suicide gene that is intended to selectively destroy the target cell. Examples of cytotoxic genes include

GAL Venv (e.g., Genbank Acc. No. M26927), HSVTK (e.g., Genbank Acc. Nos. AF057310, X01712), cytosine deaminase (e.g., Genbank Acc. No. S56903), nitroreductase (e.g., Genbank Acc. No. A23284), or VSV glycoprotein G (e.g., Genbank Acc. No. X03633).

In one embodiment of the invention, a therapeutic transgene according to the invention, encodes a protein with both direct cytotoxic and immunostimulatory properties (e.g., fusogenic proteins) which is cloned downstream of a cell type-specific promoter and an HSE. One example of such a protein is the fusogenic membrane glycoprotein (FMG) (Batman, et al., Cancer Res. 60: 1492-1497 (2000); Diaz, et al. Gene Three. 2000; *In press*; Fielding, et al., Hum Gene Three. 11: 817-826 (2000). FMGs kill tumor cells by causing fusion between cells expressing the FMG and neighboring cells which express the receptor for the FMG.

The fusogenicity of fusogenic proteins means that large local bystander effects can be achieved, where non-expressing cells can be recruited into large multi-nucleated syncytia and eventually killed. Indeed, the bystander killing of an FMG *in vitro* is at least one log higher than that of the conventional suicide genes, HSVtk or CD, in most tumor cell lines tested so far (Bateman, et al., *supra*). In addition, expression of viral FMG is also highly immunostimulatory as judged by the immunogenicity of FMG-expressing vaccines and by the induction of stress related proteins such as inducible heat shock proteins during the killing process (Bateman, et al., *supra*, Diaz, et al., *supra*). These dual properties of high local killing capacity and immunostimulatory activity make fusogenic proteins attractive transgene products for use in gene therapy of cancer.

Fusogenic proteins are known in the art and include, but are not limited to, viral FMGs such as type G membrane glycoproteins of rabies virus, Mokola virus, vesicular stomatitis virus, and Togaviruses, as well as murine hepatitis virus JHM surface projection protein, porcine respiratory coronavirus spike glycoprotein, porcine respiratory coronavirus membrane glycoprotein, avian infectious bronchitis spike glycoprotein and its precursor, bovine enteric coronavirus spike protein, paramyxovirus SV5 F protein, Measles virus F protein, canine distemper virus F protein, Newcastle disease virus F protein, human parainfluenza virus 3 F protein, simian virus 41 F protein, Sendai virus F protein, human respiratory syncytial virus F protein, Measles virus hemagglutinin, simian virus 41 F protein, Sendai virus F protein, human

respiratory syncytial virus F protein, Measles virus hemagglutinin, simian virus 41 hemagglutinin neuraminidase proteins, human parainfluenza virus type 3 hemagglutinin neuraminidase, Newcastle disease virus neuraminidase, human herpesvirus 1 gH, simian varicella virus gH, human herpesvirus gB proteins, cercopithecine herpesvirus gB proteins, Friend murine leukemia virus envelope glycoprotein, influenza virus hemagglutinin, poxvirus membrane glycoprotein, Russian Far East encephalitis virus membrane glycoprotein, Venezuelan equine encephalitis virus membrane glycoprotein and varicella virus membrane glycoprotein. FMGs and their sequences are described further in U.S. Provisional Application Serial No. 60/193,977, filed March 31, 2000, the entirety of which is incorporated by reference herein.

As discussed above, the ability to target gene expression to tumor cells is an essential prerequisite for safe and effective gene therapy of cancer. The more potent the therapeutic gene that is used (i.e., the more toxic), the greater is the need for tight control of its expression to avoid toxicity in non-cancer cells. For example, transcriptional elements which lead to 'phenotypic' tissue specificity of transgene expression with a GM-CSF therapeutic gene (Diaz, et al., J Virol., (1998) 72: 789-795, incorporated by reference herein) are insufficient to limit the expression of a much more potent FMG cDNA to the specific cell types in which the GM-CSF gene is expressed.

Therefore, in one embodiment of the invention, an FMG encoding sequence is operably linked to a highly tumor-specific promoter which results in FMG expression greater than 100-fold to 1000-fold in tumor cells compared to non-tumor cells. In one embodiment of the invention, the positive feedback loop described above is used to amplify the tumor specific gene expression of an FMG. In this embodiment, an amplification promoter element, such as an HSE, is cloned upstream of a highly tumor-specific promoter which in turn is cloned upstream of an FMG-encoding sequence. The tumor specific expression of FMG is validated by performing a nested polymerase chain reaction (PCR) protocol, to verify that the FMG gene is silent in all cell types except the specific tumor type corresponding to the tumor-specific promoter. In one embodiment, the expression of the FMG gene is evaluated in at least 6 different cell types (e.g., different types of normal tissues and/or different types of tumors), at least 5 of which must not express FMG.

1 The positive feedback loop according to the invention has three principal advantages
2 where a gene encoding a cytotoxic protein is used as the therapeutic transgene, and HSE and
3 HSF-1 are used as the amplification promoter element, and amplification promoter element
4 transcription element, respectively: 1) it leads to highly tissue specific expression of a very
5 potent cytotoxic gene; 2) it allows increasing levels of the cytotoxic gene to be expressed which
6 leads to very effective local tumor cell killing; and 3) it also leads to the expression of HSF-1
7 which transactivates endogenous HSE elements and leads to cell type-specific expression of
8 cellular stress proteins, including hsp70 and natural killer (NK) cell receptors. The induction of
9 heat shock proteins (hsps) is a highly potent immune adjuvant to tumor cell killing and leads to
10 the generation of long term anti-tumor immunity. See, e.g., Melted, et al., Nat Med. 4: 581-587
(1998); Todryk, et al., J Immunol 163: 1398-1408 (1999); Srivastava, et al., Immunity 8: 657-
665 (1998), the entireties of which are incorporated herein by reference.

11 Therefore, in one embodiment, a construct is provided which comprises a stress-
12 responsive transcriptional activator (e.g., HSF-1) encoding gene, and the expression of the FMG
13 is responsive to a stressor (e.g., heat). However, in a further embodiment, a mutant form of the
14 stress-responsive transcriptional activator which is constitutively active even in the absence of
15 stress (see, Zuo, et al., Mol. Cell. Biol. 15: 4319-4330 (1995), who disclose constitutively active
16 HSF-1 proteins) is cloned downstream of an FMG cDNA. In this embodiment, low levels of
17 expression from the cell type-specific promoter (e.g., tissue-specific and/or tumor-specific
18 promoter) is observed to initiate expression of both FMG and the transcription activator
19 encoding sequences; the expression of both transgenes is amplified as the transcription activator
20 sequences accumulate in the cell.

Delivery of Nucleic Acid Constructs to Target Tissues

21 Nucleic acid molecules and constructs providing therapeutic transgenes under the control
22 of highly cell-type specific promoters and amplification promoter elements, can be incorporated
23 into a vector and administered to any mammal, including a human. Many such vectors are
24 commercially available, and other suitable vectors can be readily prepared and obvious to the
25 skilled artisan. The exact design of the vector depends on such factors as the choice of the host
cell to be transformed and/or the type of protein desired to be expressed. Suitable vectors can be

produced by ligating the desired construct into a plasmid or viral vector suitable for expression in eukaryotic cells (see, for example, Broach, et al., *Experimental Manipulation of Gene Expression*, ed. M. Inouye (Academic Press, 1983) p. 83; *Molecular Cloning: A Laboratory Manual*, 2nd Ed., ed. Sambrook, et al. (Cold Spring Harbor Laboratory Press, 1989) Chapters 16 and 17, the entireties of which are incorporated by reference herein).

Examples of vectors that can be used include, but are not limited to, plasmids such as pBR322, pUC, or ColE1; adenovirus; Sindbis virus; simian virus 40; cytomegalovirus; and retroviral vectors such as murine sarcoma virus, mouse mammary tumor virus, Moloney murine leukemia virus, and Rous sarcoma virus. Bacterial vectors can be used, such as *Salmonella* spp., *Yersinia enterocolitica*, *Shigella* spp., *Vibrio cholerae*, *Mycobacterium* strain BCG, and *Listeria monocytogenes*. Minichromosomes such as MC and MC1, bacteriophages, cosmids (plasmids into which phage lambda cos sites have been inserted) and replicons (genetic elements that are capable of independent extrachromosomal replication).

The vectors described above can additionally comprise sequences encoding one or more selectable markers, including, but not limited to, the gene that encodes dihydrofolate reductase and the genes that confer resistance to neomycin, tetracycline, ampicillin, chloramphenicol, kanamycin and streptomycin resistance. To improve incorporation into the genome of the target cell (if desired), a retroviral vector can be used, and long terminal repeat (LTR) sequences can be added on either side of the expression construct (see, e.g., Vile, et al., *Virology* 214: 307-313 (1995), the entirety of which is incorporated by reference herein).

Delivery of a therapeutic transgene under the control of a highly cell-type specific promoter can be by any means known in the art, including oral or intranasal administration; intramuscular, intradermal, intraperitoneal, or subcutaneous injection, including injection using a biological ballistic gun ("gene gun"). Administration of the therapeutic transgene can be repeated at any desired interval as needed to achieve therapeutic efficacy. Additional components can be added to a vector to improve its selective delivery to target cells and to repress its delivery to non-target cells. Examples of approaches that can be used include host range extension, entry enhancement, and host range restriction, as described in Peng and Russell,

Cur. Opin. Biotech. 10: 454-457 (1999), the entirety of which is incorporated herein by reference.

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples, which are provided herein for purposes of illustration only and are not intended to limit the scope of the invention.

Examples

Plasmids and Cell Lines

For the analysis of melanoma specific gene expression, plasmids and viruses were transduced into either melanoma (MeWo, Me1624, A378M, B16 or 1735) or non-melanoma (HT1080; 293; Vero, Tel.CeB6, HeLa, CMT93) cell lines. The human tyrosinase promoter plasmids (300 base pairs; 115 base pairs or 65 base pairs) are as described by Bentley et al., *supra*, and Diaz, et al, *supra*. The TDE-SVO plasmid consists of three repeated copies of the 20 base pairs Tyrosinase Distal Element (TDE) upstream of the minimal SV40 basal promoter (Promega) (Diaz, et al. J. Virol. (1998) 72: 789-795, the entirety of which is incorporated by reference herein). The cDNA of the mutated HSF-1 transcription factor is described in Zuo, et al., Mol. Cell Biol. 15: 4319-4330, (1995) (the entirety of which is incorporated by reference herein) and consists of a deletion of the wild type HSF-1 cDNA corresponding to amino acid positions 202-316. The HSE element - 5'- AGAATGTTCTAGAAG-3' was synthesized as a consensus sequence which confers heat shock and HSF-1 responsiveness on heterologous genes as described in Amin, et al., Mol. Cell Biol. 8: 3761-3769 (1988) and Goldenberg, et al., J. Biol. Chem. 263: 19734-19739 (1988), the entireties of which are incorporated by reference herein.

To assess promoter/enhancer strengths, plasmids were constructed using standard techniques such that different promoters and promoter/enhancer fragments were placed upstream either of the Chloramphenicol Acetyl Transferase (CAT) gene (Diaz, et al, *supra*), the human GM-CSF gene (Wong, et al., Science 228: 810-815 (1985), the entirety of which is incorporated by reference herein) or the cDNA of the Gibbon Ape Leukaemia Virus fusogenic membrane glycoprotein (GALV-FMG) (Bateman, et al. Cancer Res. 60: 1492-1497 (2000); Fielding, et al.,

supra, the entireties of which are incorporated by reference herein). Levels of gene expression were assayed using either CAT assays (Diaz, et al., *supra*), by measuring levels of human GM-CSF secreted from the plasmids by ELISA (Pharmingen) or by semi-quantitative RT-PCR as described below.

Hybrid LTR retroviral vectors were constructed from the parental Mo-MLV retroviral plasmid pBabePuro (Morgenstern, et al., Nucleic Acids Research 18: 3587-3596 (1990), the entirety of which is incorporated herein). Manipulations to the 3'LTR were made in the plasmid pSKLTR followed by reassembly into the pBabePuro plasmid through Clal-PvuI ligations as described in Diaz, et al., *supra*.

Analysis of Gene Expression from Cells by Reverse Transcriptase Polymerase Chain Reaction

RNA was prepared from cultured cell lines with the RNA Easy[®] kit (Qiagen) according to the manufacturer's instructions. RNA concentrations were measured and 1 µg total cellular RNA was reverse transcribed in a 20 µl volume using oligo-(dT) as a primer and Moloney murine leukaemia virus reverse transcriptase (Pharmacia LKB Biotechnology, Milton Keynes, U.K.). A cDNA equivalent of 1ng RNA was amplified by the polymerase chain reaction using primers specific for the target genes. PCR was performed in a 50 µl reaction mixture with 250µM of each dNTP, 100nM of primers, 5µl of 10x buffer (HT Biotechnology Ltd, Cambridge, U.K.), and 1 unit of super Taq DNA polymerase (HT Biotechnology Ltd, Cambridge, U.K.), using 30 cycles. The reaction mix (25µl samples) was analyzed by agarose gel electrophoresis (1%) in TAE buffer containing 0.2µg/ml ethidium bromide. In all experiments, a mock PCR (without added DNA) was performed to exclude contamination. To exclude carry over of genomic DNA during the RNA preparation step, controls were also carried out in which the reverse transcriptase enzyme was omitted.

Cell Transfection and FMG-mediated Cell Killing Assays

To assess the cytotoxicity of the GALV FMG driven by the HSE-Tyr-300, Tyr-300 or the CMV promoters, cells were plated in 6 well plates at a density of 5×10^5 cells per well. 24 hours later, each well was transfected with 5µg of the appropriate plasmid DNA using calcium

phosphate transfection (Profection[®], Promega, WI) according to the manufacturer's instructions. 4 hours later the cells were washed three times in serum free medium and then incubated in normal, serum containing medium for a further 72 hours. Plates were either counted for living cells to assess the levels of cell survival (as described in Bateman, et al., *supra*) or were stained with Crystal violet to obtain a qualitative, pictorial representation, of the degree of cytotoxicity. To determine the heat shock sensitivity of the HSE element, the appropriate plates were sublethally heat shocked at 42°C for 30 minutes.

Generation of Retroviral Vector Stocks

The GALV FMG cDNA was subcloned into the pBabePuro vector backbone at the *EcoRI* sites in the polylinker using standard techniques. Subsequently, the cDNA for the HSF-1d202-316 transcription factor (Zuo, et al., *supra*) was subcloned downstream of the GALV cDNA into the *Sall* site of the pBabePuro polylinker leaving a 24 base pair linker to separate the GALV and HSF-1d202-316 genes. This C-type vector was packaged into viral particles by transfection of 5 µg of plasmid DNA into the 293INT cell line which stably expresses the MoMLV *gag* and *pol* genes but no envelope along with 5µg of the plasmid pMD.G encoding the VSV-G envelope protein (see, Naldini, et al., Science 272: 263-266 (1996); Zufferey, et al., Nat Biotechnol. 15: 871-875 (1997), the entireties of which are incorporated by reference herein).

Transfections were carried out in a 10 cm plate out using the Profection (calcium phosphate co-precipitation) method (Promega, WI). 48-72 hours following transfection, cell supernatants were recovered, filtered through a 0.45 µm filter and either used directly for infection or frozen at -80°C.

Viral infections were performed by exposing exponentially growing target cells, (either melanoma, Mel624 or MeWo) or non-melanoma (HT1080, 293 or Te1CeB6), to different dilutions of viral supernatants in serum free medium for 4 hours in 24 well plates. The infectious medium was then removed and cells were washed three times before being allowed to grow in normal growth medium for a further 120 hours. At this stage, infected cultures were counted for living cells to assess the levels of cell survival.

EXAMPLE 1

Identification Of A Highly Melanoma Specific 300 Hi, Element Of A Human Tyrosinase Promoter

5 The specificity of enhancer + promoter elements for expression of a CAT reporter gene was compared in human melanoma cell lines (B 16, A378M) and human non-melanoma cell lines (HT1080, 293, Tel.CeB6). Plasmid construction and transfection were as described in Diaz et al., *supra*. Reverse transcriptase PCR was performed as described in Vile et al., *supra*.

10 The results of RT-PCR analysis are shown in Figure 2. The TDE-SV40 element is clearly preferentially active in melanoma cells, but this specificity is not sufficient to prevent a highly potent gene such as GALV from being toxic in non-melanoma cells.

15 Different lengths of the basal promoter from the human tyrosinase gene were surveyed in search of a promoter which is genuinely transcriptionally silent in non-melanoma cells. Using a sensitive nested RT-PCR assay with chloramphenicol acetyltransferase (CAT) as the reporter gene (the primers used were 5'-ATGGAGAAAAAATCACTGGA-3' (SEQ ID NO:3) and 5'-GAGACGAAAAACATATTCTCA-3' (SEQ ID NO:4)), a 115 base pair element that was previously reported to be melanoma -pecific (Bentley, et al., *supra*) was found to possess transcriptional activity in some of the non-melanoma cells tested (Figure 3A). However, a 300 base pair element (Tyr300) was transcriptionally silent in all of the non-melanoma cell lines tested, yet retained activity in human and murine melanoma cells (Figure 3B).

EXAMPLE 2

HSE Adds Inducibility By Heat Shock Proteins To A Tyr300-SV40 Promoter

25 A consensus HSE sequence (5'-AGAATGTTCTAGAAG-3', SEQ ID NO:2) was synthesized and incorporated upstream of the melanoma-specific Tyr300 promoter element controlling a reporter gene encoding GC-CSF. This HSE consensus sequence confers heat shock inducibility on reporter genes (Zuo et al, *supra*; Goldenberg et al., J. Biol. Chem. 263: 19734-39 (1988)). Two plasmids were made in which HSE was separated from the Tyr300 promoter by

either one full turn (10 nucleotide bases) of the DNA helix (HSE-Tyr300-FULL-GM-CSF) or by one-half turn of the helix (HSE-Tyr300-HALF-GM-CSF).

Transient transfection of a human non-melanoma line (HT1080) with 20 ug of either a Tyr-300-GM-CSF plasmid, an HSE-Tyr 300-FULL-GM-CSF plasmid, or an HSE-Tyr 300-HALF-GM-CSF plasmid generated no detectable GM-CSF product 72 hrs following transfection (data not shown). Co-transfection of these same cells with HSF-1 cDNA also failed to produce any GM-CSF production (see Figure 4, condition 1). Human melanoma cells (MeWo cell line) transfected with 20 ug of either the Tyr 300-GM-CSF (Figure 4, condition 2) or the HSE-Tyr 300-FULL-GM-CSF plasmid (Figure 4, condition 6) express only very low amounts of GM-CSF; similar results were obtained with the HSE-Tyr 300-HALF-GM-CSF plasmid (not shown).

This demonstrates that Tyr 300 is a very weak promoter. However, transfection of MeWo cells with 20 µg of the TDE-SV40-GM-CSF plasmid (Figure 4, condition 3) leads to easily detectable levels of GM-CSF production (see also Diaz et al., J. Virol. (1998) 72:789-95). In the presence of either heat shock (42 °C, 30 minutes; Figure 4, condition 4) or co-transfection with 20 µg of mHSF-1 plasmid (Figure 4, condition 5), GM-CSF production is increased significantly following transfection with the HSE-Tyr 300-FULL-GM-CSF plasmid and increased to a lesser degree using the HSE-Tyr300-HALF-GM-CSF plasmid (not shown). These experiments demonstrate that the HSE-Tyr300 base pair promoter is both tissue-specific and can be induced by mHSF-1.

EXAMPLE 3

Induction Of Hsp70 Using HSE And Constitutively Active Mutant HSF-L.

Hsp70 expression was probed by Western blotting using antibody BRM-22 (Sigma Chemical Co., St. Louis, MO) in B16 cells stably expressing constitutively active human mHSF-1 (deletion 202-316). The resulting immunoblot is shown in Figure 5. Lysates of untransfected B-16 cells are shown in lane 1. Lane 2 shows the pooled population of HSF-1 transfected colonies. Lanes 3-7 show clones of individual HSF-1 transfected colonies. Mock transfected cells or cells transfected with irrelevant plasmids did not show induction of hsp70. Expression of

hsp70 correlated exactly with expression of mHSF-1 assayed by Western Blotting of the pools and clones (data not shown).

EXAMPLE 4

Selective Elimination Of Human Melanoma Tumor Growth Using A Tyr300-GALV

Construct

HT1080 (human fibrosarcoma) or Mel624 (human melanoma) tumors were seeded subcutaneously in nude mice (10^6 cells per mouse). Growing tumor cells were transduced *in situ* with 10 ug/tumor of CMV- β -Gal, CMV-GALV or Tyr300-GALV plasmid DNA complexed with Efectene lipid (Qiagen). The CMV β -Gal plasmid was constructed by cloning β -galactosidase cDNA into the EcoRI site of the plasmid pCR3 (Invitrogen) with expression driven by the CMV promoter. The CMV-GALV plasmid was constructed by cloning GALV cDNA into the EcoRI site of pCR3 with expression driven by the CMV promoter. The Tyr300-GALV plasmid was constructed by cloning the HSE-Tyr300 element upstream of the GALV cDNA into the EcoRI site of pCR3; for this condition the cells were cotransfected with mHSF-1 in pCR3. Ten mice were injected per group. At seven days following DNA injection of HT1080 tumors, those injected with CMV-GALV plasmid began to regress compared with the progression of tumors in the other two groups (Figure 7A). In the same mice at 13 days after transduction, tumor size in some groups reached 1.2 cm in the longest diameter, at which point those animals were sacrificed. The tumors in the CMV-GALV-injected group had all regressed and had been eliminated (Figure 7B). Animals in which tumor size had not reached 1.2 cm by day 13 were maintained and tumor size was followed.

By day 30 following transduction of tumors, nearly all mice in the CMV- β -Gal and TYR-GALV groups had eventually developed tumors which reached 1.2 cm in diameter and were sacrificed (Figure 7C). Long term tumor-free mice (shown over each group) were scored as those having no detectable tumor by the end of the experiment. Progression of transduced human melanoma tumors, Mel624, was similar to that shown for the HT1080 tumors. By the end of the experiment (day 30 after transduction), 90% the tumors transduced with the CMV-GALV plasmid had been eliminated. The one tumor recurrence in this group developed 23 days

following DNA delivery. In contrast, 100% of the tumors transduced with the TYR-GALV plasmids were eliminated and no regrowths were observed.

Example 5

The Efficacy Of Transcriptional Targeting Depends On The Potency Of The Transgene Being Expressed

In one embodiment, the cDNA of the GALV FMG protein was cloned downstream of the TDE-SV40 element to induce melanoma-specific cell killing *in vitro*. Transfection of the TDE-SV40-GALV plasmid into three different human melanoma cell lines induced large amounts of cell fusion 24-48 hours following transfection, at levels comparable to that produced by a CMV-GALV construct. When transfected into 5 human non-melanoma cell lines, the TDE-SV40-GALV construct showed a clear lag period in the formation of syncytia compared to CMV-GALV. However, in the majority of the lines, significant amounts of cell fusion subsequently developed after 72-96 hours as shown in Table 1, below.

Cell Line	Syncytium Formation 24 hrs Post Transfection	
	CMV GALV	TDESV40 GALV
HT1080	+++	+/-
293	+++	+
Tel	+++	+/-
Vero	+++	-
MeWo	+++	+++
A378M	+++	+++
Cell Line	Syncytium Formation 96 Hours Post Transfection	
	CMV-GALV	TDESV40-GALV
HT1080	+++	++
293	+++	+++
Tel	+++	++
Vero	+++	+
MeWo	+++	+++
A378M	+++	+++

+++ : 70-100% of all the cells on the plate have been recruited into syncytia; ++: 30-70% of cells are within syncytia; +: between 10 and 30% are within syncytia; and +/-: means that fewer than 10% of cells are within syncytia.

To confirm that expression from the TDE-SV40 enhancer/promoter is genuinely melanoma-preferential, a semi-quantitative RT-PCR assay was used (Figure 8). Levels of transcripts from the TDE-SV40 promoter were significantly lower than those from the CMV driven construct in all non-melanoma cell lines, but were close to equivalent in the melanoma cell lines (Figure 8). Thus, the melanoma cell specificity of TDE-SV40 is real but is not sufficient to prevent a highly potent gene such as GALV from being toxic in a proportion of non-melanoma cells.

Example 6

Identification Of An Element Of The Human Tyrosinase Promoter That Is Transcriptionally Silent In Non-Melanoma Cells But Retains Activity In Melanoma Cell Lines

In one embodiment, fragments which ranged from +80 to -65, -115 or -300 from this basal Tyr promoter were evaluated using both CAT expression and RT-PCR assays to screen for expression. Both the 65 base pair and the 115 base pair fragments of the promoter showed some transcriptional activity by RT-PCR in some, or all, of the non-melanoma cells tested (Figure 9A). In contrast, using a sensitive nested RT-PCR assay, the 300 base pair element of the tyrosinase promoter was transcriptionally silent in all of the non-melanoma cells tested but retained activity in the human and murine melanoma cells (Figure 9B). However, when the CAT, GM-CSF, or GALV genes were cloned downstream of the 300 base pair promoter, levels of transgene expression were low, and melanoma cells transfected with the Tyr 300-GALV construct showed limited cell cytotoxicity at only about 10% of the levels produced by CMV-GALV (Figure 14).

Example 7

Amplification Of Low Level Expression From A Weak, But Tissue-Specific, Promoter Using A Second Transcriptional Regulatory Element

Since levels of expression from highly cell type-specific promoters are generally not therapeutic, even when highly potent genes (e.g., cytotoxic) genes such as FMGs are used, in one

embodiment, an amplification promoter element was operably linked to an FMG under the control of a highly cell type-specific promoter. In one embodiment, an amplification promoter comprising a consensus HSE sequence (5'- AGAATGTTCTAGAAG-3') modified from the construct described in Goldenberg, et al., *supra*, and Todyry, et al., *supra*, was synthesized

5 In order to investigate whether it was necessary to optimize the topological spacing of the HSE element relative to any of the 5 characterized important DNA/protein binding sites within the 300 base pair element of the tyrosinase promoter, plasmids were made in which the HSE element was separated from the C nucleotide at position -300 of the Tyr-300 promoter by either no nucleotides or one full turn of the DNA helix (HSE-Tyr 300-FULL) or by a stuffer fragment
10 representing one half turn of the helix (HSE Tyr-300-HALF) (Figure 9A). Both HSE-Tyr 300-GM-CSF plasmids transfected into MeWo melanoma cells produced the same low levels of GM-CSF as the Tyr300-GM-CSF plasmid (Figure 9B). However, when the transfected cells were heat shocked at 42°C for 30 minutes, 24 hours following transfection, GM-CSF production was increased, but only in cells transfected with the HSE-Tyr300 plasmids (Figure 9B).

15 Several experiments demonstrated up to a three fold increase in GM-CSF production from melanoma cells transfected with the HSE-Tyr 300-FULL construct compared to the HSE-Tyr 300-HALF construct (data not shown). The non-melanoma line HT1080, similarly treated, did not produce any GM-CSF either with or without heat shock *in vitro* (data not shown). Similar results were obtained from RT-PCR studies performed on melanoma and non-melanoma
20 cells transfected with the HSE-Tyr 300-FULL or HSE-Tyr 300-HALF constructs, confirming both the tissue specificity of GM-CSF expression from melanoma cells, as well as the increased level of message using the HSE-Tyr 300-FULL construct (data not shown). Hence, the HSE element cooperates with the Tyr300 base pair promoter to induce tissue-specific expression, an effect which can be optimized by engineering the topology of the spacing of the two separate
25 elements.]

Example 8

Transcriptional Transactivation Of The HSE-Tyr300 Base Pair Tissue-Specific Promoter Is Possible Using Mutant HSF-1

When the HSE-Tyr-300-FULL element was used to express the GALV FMG, transfection was unable to eradicate melanoma cells *in vitro* to the same extent as the CMV promoter (Figure 14). Therefore, in one embodiment, constitutively active forms of HSF-1 were used to increase levels of expression from the tissue specific HSE-Tyr300-FULL element.

A deleted, mutant form of HSF-1, HSF-1d202-316, was used in which deletion of amino acids 202-316 removes the sensitivity to stress dependent activation and nuclear translocation.

The protein is constitutively active in the absence of cellular stress while retaining the DNA and protein binding domains required to transactivate gene expression through HSE. Co-expression of HSF- 1d202-316 was demonstrated to transactivate the very weak, but highly specific, HSE-Tyr 300 promoter (Figure 10). When HSF1d202-316 was co-transfected into MeWo melanoma cells along with the Tyr 300-GM-CSF construct, no GM-CSF production could be detected. However, when HSF-1d202-316 was co-transfected with the HSE-Tyr 300-FULL-GM-CSF construct, levels of GM-CSF were increased significantly to a level similar to that produced by heat shock (Figure 9B). Importantly, cotransfection of HSE-Tyr-300-GM-CSF with HSF-1d202-316 into non-melanoma cells still gave no detectable GM-CSF production (Figure 9B). Therefore, even low levels of HSF-1d202-316 (as provided in a transient co-transfection assay) were capable of transactivating the HSE-Tyr300 base pair promoter element while retaining the tissue specificity of the tyrosinase promoter.

Example 9

The HSE Transcriptional Control Element Can Be Used To Transactivate Gene Expression From The Melanoma-Specific Tyr-300 Promoter

In one embodiment, the HSE-Tyr 300 transcriptional regulatory element was used in tandem with the HSF-1d202-316 transcription factor, to regulate highly tissue-specific

expression even of a very potent cytotoxic genes (Figure 11) and to provide an immunostimulatory effect.

In one embodiment, murine B16 cells were co-transfected with HSE-Tyr-300-GALV and HSF-1d202-316 plasmids. Importantly, B16 cells are not fused by expression of the GALV FMG because they lack the Pit-1 receptor. RT-PCR was used to follow expression of the transgenes (Figure 12). The co-transfected HSF-1d202-316 was expressed within 24 hours of transfection. However, the GALV transgene expressed from the HSE-Tyr element was not detected in appreciable amounts until 72 hrs following transfection (Figure 12), presumably because sufficient levels of HSF-1d202-316 were required to build up in order to transactivate the HSE element. In addition, following appearance of mRNA for the transfected HSF-1d202-316, transactivation of endogenous hsp70 was detected 24 hrs later. These data confirm both the operation of the feedback loop at the transcriptional level and the induction of endogenous heat shock and stress response genes. The latter induction provides effective adjuvant functions for immunostimulation.

Example 10

The HSE-Tyr-300/HSF-1 Feedback Loop Can Be Used To Kill Melanoma Cells Specifically And Efficiently

To test the efficacy of the transcriptional feedback loop *in vitro*, the HSE-Tyr300 GALV construct was transfected into non-melanoma human cells, Tel.CeB6 (Figures 13A and B) or HT1080 (data not shown). The only significant toxicity was seen in the cells transfected with the CMV-GALV construct (Figure 13A). In contrast, both the HSE-Tyr-300 and Tyr-300-GALV constructs gave low levels of toxicity when transfected into a melanoma line, Mel624 (Figures 13C, 13D) or similarly the MeWo line (data not shown). Quantitation of cell survival showed that the HSE-Tyr-300 construct gave small but significantly enhanced killing of Mel624 cells with respect to the Tyr-300 construct, presumably due to the proposed activation of the HSE-Tyr-300 element through induction of endogenous HSF-1 through GALV-mediated cell killing.

However, greatly enhanced toxicity was observed with transfection of the HSE-Tyr-300-GALV constructs when the cells were either heat shocked or co-transfected with HSF-1d202-316 (Figure 13C, D). That the latter effects were operative through HSF-1d202-316 regulation were confirmed by the demonstration that increasing amounts of co-transfected HSF-1d202-316 led to proportional increases in killing of melanoma cells, whereas no killing was observed with increasing concentrations of an irrelevant co-transfected β -Gal plasmid (Figures 13E, F). Taken together, these data show that it is possible to control highly tissue-specific expression of GALV FMG either through the application of heat itself, enabling locoregional control of gene expression (see, e.g., Blackburn, et al., Cancer Res. 58: 1358-1362, (1998), the entirety of which is incorporated by reference), or through co-expression of the HSF-1d202-316 transcription factor.

Example 11

Expression Of HSF-1d202-316 Induces Hsp70 And Other Stress Related Proteins

As well as leading to direct cytotoxicity through FMG-mediated fusion, the presence of the HSF1d202-316 transcription factor leads to activation of endogenous HSEs upstream of stress response genes, including hsp70 (Baler, et al., Mol Cell Biol; 13: 2486-2496 (1993); Zuo, et al., *supra*). Induction of hsp70 is potentially immunostimulatory, but optimally so, if it occurs during cell killing *in vivo*. Expression of HSF-1 is immunotherapeutic, through activation of endogenous HSE elements. Transfection of HSF-1d202-316 induces expression of hsp70 mRNA (see Figure 12) and induction can be detected at the level of protein expression in a variety of human and murine cell lines (data not shown). HSF-1d202-316 additionally activates expression of other stress-related proteins which also enhance the immunogenicity of the dying tumor cells, such as MICB, a ligand for the NK activatory receptor NKG2D (data not shown).

Example 12

The Complete HSE-Tyr300-FMG-HSF-1 Feedback Loop Can Be Incorporated Within The Context Of A Hybrid LTR Retroviral Vector

In one embodiment, the HSE-Tyr300 element was cloned into the 3'LTR of the Mo-MLV derived retroviral vector pBabe Puro (Morgenstern, et al., *supra*). The HSE-Tyr300 enhancer/promoter was placed in the 1J3 region of the viral LTR as described in Diaz, et al., *supra*, replacing the viral enhancer and promoter regions of the U3 region of the LTR with the heterologous enhancer/promoter elements (HSE-Tyr-300). Simultaneously, the GALV-FMG cDNA was cloned into the polylinker of the vector. As an added strategy to decrease the chances of initiating the feedback loop in non-melanoma cells, the HSF-1d202-316 cDNA was cloned downstream of the GALV cDNA, separated from it by a linker of 24 base pair (Figure 14A), thereby exploiting a strategy as described by Cosset, et al., *supra*.

The lack of an internal ribosome entry site (IRES) between the first (GALV) and the second (HSF-1d202-316) gene in this construct means that only a small proportion of the total mRNA molecules produced from the HSE-Tyr-300 promoter will undergo internal initiation of translation of the second transgene (Cosset, et al., *supra*). Hence, only those cells in which the promoter is sufficiently active will be able to generate enough mRNA such that any of the second gene is ever translated. Therefore, any non-melanoma cell, in which there is appreciable leakiness of the Tyr-300 element, should still have very low levels of expression of the feedback gene (HSF-1d202-316), significantly reducing the chances of the feedback loop ever being initiated.

Following packaging, reverse transcription, and integration of the retroviral vector, an integrated provirus of structure shown in Figure 14A was produced. Virus was packaged from the 293INT cell line with the VSV-G envelope and used to infect MeWo or Mel624 melanoma and HT1080, 293 or Tel non-melanoma cell lines. The ability of different packaged viral vectors to induce syncytia and cytotoxicity was followed with time (Figures 14B, 14C). Whereas the control vector pBabe-Puro generated no detectable syncytia in either melanoma or non-melanoma cell lines, the positive control vectors pBabe-GALV and pBabe GALV-HSF-1 (wt LTR), in which the GALV cDNA is driven by the Mo-MLV LTR, both induced syncytial

formation within 24 hours of infection of all cell types. This led to extensive cell killing over time.

In contrast, the pBabe-GALV-HSF-1 (HSE-Tyr LTR) vector produced no detectable syncytia in either of the three non-melanoma cell lines, indicating that the LTR was unable to drive expression of the GALV cDNA. Further no vector-induced syncytia were observed in infected 293 cells. These cells express the adenoviral E1A gene, which transactivate expression of cellular hsp70 through the HSE element. Despite constitutive transactivation of the HSE element, the tissue specificity of the TYR-300 element was tight enough to prevent initiation of the feedback loop in these cells. However, in the two melanoma cell lines tested, syncytia were induced, but only 48-72 hours following the appearance of syncytia with the wild type LTR. Presumably this is due to the time lag required for the build up to sufficient levels of HSF-1d202-316 protein to transactivate the HSE element. Thereafter, syncytial development was very aggressive and the pBabe-GALV-HSF-1 (HSE-Tyr LTR) was able to kill over 90% of target melanoma cells, comparable to that of the wild type LTR-driven GALV vector. Finally, to confirm that longer periods of culture did not allow pBabe-GALV-HSF-1 (HSE-Tyr LTR) to induce syncytia, infected TelCeB6 cells were passaged for another week and inspected daily for syncytia. None were detected. Therefore, although there is a clear time delay in the ability of the pBabe-GALV-HSF-1 (HSE-Tyr LTR) vector to become effective, the vector is both highly tissue-specific and effective.

Variations, modifications, and other implementations of what is described herein will occur to those of ordinary skill in the art without departing from the spirit and scope of the invention as claimed. Accordingly, the invention is to be defined not by the preceding illustrative description but instead by the spirit and scope of the following claims.

What is claimed is:

CLAIMS

1. A composition comprising a nucleic acid molecule, said nucleic acid molecule comprising:
 - a cell type-specific promoter for activating the expression of a gene in a specific cell type;
 - a therapeutic gene sequence operably linked to said cell type-specific promoter;
 - an amplification promoter element for amplifying transcription of said therapeutic gene in said specific cell type; and
 - a sequence encoding a transcription activator, said transcription activator for activating said amplification promoter element.
2. The composition of claim 1, wherein said cell type-specific promoter is a tissue-specific promoter.
3. The composition of claim 1 or 2, wherein said cell type specific promoter is a tumor-specific promoter.
4. The composition of claim 1, wherein said amplification promoter element is a stress inducible promoter element.
5. The composition of claim 1, wherein said nucleic acid molecule comprises said sequence encoding said transcription activator.
6. The composition of claim 1, wherein said sequence encoding said transcription activator sequence and said therapeutic gene sequence are on different nucleic acid molecules.
7. The composition of claim 4, wherein said stress inducible promoter element is a heat shock element (HSE).
8. The composition of claim 3, wherein the tumor is a melanoma and the cell type-specific promoter is selectively active in melanoma cells.

9. The composition of claim 1, wherein the cell type specific promoter is human Tyr300 (SEQ ID. NO. 1).
10. The composition of claim 1, wherein the amplification promoter element comprises at least one human HSE consensus sequence.
11. The composition of claim 1, wherein said therapeutic gene is a cytotoxic gene.
12. The composition of claim 11, wherein said cytotoxic gene encodes a fusogenic protein.
13. The composition of claim 11, wherein the cytotoxic gene is GALVenv, HSVTK, cytosine deaminase, nitroreductase, or VSV-G glycoprotein.
14. The composition of claim 1, wherein said nucleic acid molecule kills at least 80% of the cells of the specific cell type, and kills at most 10% of cells which are not of the specific cell type.
15. The composition of claim 1, wherein said nucleic acid molecule produces a level of mRNA expression which is at least 100-fold higher in cells of the specific cell type compared to cells which are not of the specific cell type.
16. The composition of claim 1, wherein said nucleic acid molecule produces a level of therapeutic gene mRNA expression which is at least 500-fold higher in cells of the specific cell type compared to cells which are not of the specific cell type.
17. The composition of claim 1, wherein said nucleic acid molecule produces a level of therapeutic gene mRNA expression which is at least 1000-fold higher in cells of the specific cell type compared to cells which are not of the specific cell type.
18. The composition of claim 1, wherein the amplification promoter element is an HSE and the transcription activator is HSF-1.

19. The composition of claim 1, wherein the transcription activator is activatable by a stressor.
20. The composition of claim 1, wherein said transcription activator is constitutively expressed.
21. The composition of claim 1, wherein said therapeutic gene and said amplification promoter element transcription activator are both operably linked to said cell type-specific promoter.
22. The composition of claim 1 or 21, wherein said therapeutic gene and said transcription activator are both operably linked to said amplification promoter element.
23. The composition of claim 18, wherein the transcription activator which is HSF-1 comprises a deletion of amino acid residues 202-316.
24. The nucleic acid molecule of any of claims 15-17.
25. A nucleic acid molecule comprising a human tyrosinase promoter operably linked to a cytotoxic gene.
26. The nucleic acid molecule of claim 25, wherein said cytotoxic gene encodes a fusogenic protein.
27. A nucleic acid molecule comprising a therapeutic gene operably linked to a cell type specific promoter and a heat shock responsive element, and further encoding a transcription activator for activating said heat shock responsive element.
28. The nucleic acid molecule of claim 27, wherein said transcription activator comprises HSF-1.
29. The nucleic acid molecule of claim 25, wherein the promoter comprises Tyr300 as shown in SEQ ID NO. 1.

30. The nucleic acid molecule of claim 28, wherein said transcription activator which is HSF-1 comprises a deletion of amino acid residues 202-316.
31. The nucleic acid molecule of claim 24, wherein said nucleic acid molecule is any of an adenoviral vector or a retroviral vector.
- 5 32. The nucleic acid molecule of claim 31, wherein said retroviral vector comprises a long terminal repeat sequence.
33. A method of treating a patient in need of tissue-selective gene therapy, comprising the step of:
- administering to the patient a composition according to any of claims
- 10 1-23.


GENE EXPRESSION BY POSITIVE FEEDBACK ACTIVATION OF A CELL TYPE-SPECIFIC PROMOTER

Abstract

A nucleic acid construct is described which provides cell type-specific expression of a therapeutic transgene. The construct utilizes a cell type-specific promoter which drives expression of the transgene. A positive feedback loop is introduced through the addition of a amplification promoter element operably linked to the therapeutic transgene and by providing, either as part of the same construct, or in a different construct, a transcription activator for activating the amplification promoter element. In one embodiment, the amplification promoter element is a heat shock response element (HSE) and the transcription activator is HSF-1. The construct enables functional targeting of a therapeutic gene while avoiding undesirable effects in non-targeted cells, by combining sufficiently high-level expression to promote a desirable therapeutic outcome with exceptional tissue specificity. A series of promoter elements, constructs, vectors, and therapeutic approaches is presented for gene therapy of tumors such as melanoma and other genetic diseases.



	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
1	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100



1	2	3	4	5	6	7	8	9	10	11	12	13
HT1080		293		Tel		Hela		B16		A378M	Marker	

Figure 2

00721391 112200




Figure 3A The Tyr115bp promoter is active in non-melanoma cells. RtPCR for expression of the CAT gene directed by the Tyr115bp promoter, in a range of non-melanoma (lanes 2-9, 11 and 13) and melanoma lines (lanes 10 and 12), indicated that expression is observed in at least 2 non-melanoma cell lines (293, lane 4 and Tel CeB6, lane 6).

00221 11:23:00




Figure 3B

0921394 112000




Figure 4




Figure 5

09721391 112200




Figure 6

000000 16E2/60

Figure 7A

A. HT1080, 7 days




Figure 7A

1-2-64

Plasmid Delivered To Tumor

Figure 7B


000000 15:22/89

Figure

C. HT1080, 30 Days

0/10 Long-term Tumor Free
(1 small tumor <0.2cm)

1/10 Long-term Tumor Free



10/10 Long-term Tumor Free

TYR-GALV

CMV-GALV

CMV-B-Gal

Plasmid Delivered To Tumor


Figure 7C

FIGURE 8

	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2423	2424	2425	2426	2427	2428	2429	2430	2431	2432	2433	2434	2435	2436	2437	2438	2439	2440	2441	2442	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---

FIGURE 9A

A.




2 3 4 5 6 7 8 9 10 11 12 13

3




•

A.



B.








FIGURE 11

HSE-Human Tyr-GALV + mHSF-1 in B16 cells



09721391 11200



PH872409_1.DIG

FIGURE 13A



[illegible]

FIGURE 13B

00221394 11200
00221394 11200




PH872409 5 DIG

FIGURE 13C

09721391.11200

Mel 624




PH872409 4.DIG

FIGURE 13D

09721391 112200
002211 10E2760


MeI 624: 5 μ g HSE-Tyr-GALV + CMV- β Gal



PH872409_2 DIG

FIGURE 13E

Me1 624: 5 μ g HSE-Tyr-GALV + mHSF-1



PH872409_3.DIG

FIGURE 13F

A.




FIGURE 14A

B

Mel 624

Syncytia Formation with Time Following Infection (hrs)

Vector	t=0	t=24	t=48	t=72	t=96	t=120
pBabe Puro	-	-	-	-	-	-
pBabe GALV	-	+	++	+++	++++	+++
pBabe GALV-HSF-1-(wtLTR)	-	+	+	+++	++++	++++
pBabe GALV-HSF-1-(HSE Tyr LTR)	-	-	-	+	+++	++++
Tel						
	t=0	t=24	t=48	t=72	t=96	t=120
pBabe Puro	-	-	-	-	-	-
pBabe GALV	-	+	++	++++	++++	++
pBabe GALV-HSF-1-(wtLTR)	-	+	+++	++++	++++	++
pBabe GALV-HSF-1-(HSE Tyr LTR)	-	-	-	-	-	-

C.





FIGURE 14C.

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



SCANNED # 14

Application deficiencies were found during scanning:

☐ Page(s) _____ of _____ were not present:
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present:
for scanning. (Document title)

☒ Scanned copy is best available. *drawings*